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EFFECTS OF LUTEINIZING HORMONE RECEPTOR EXPRESSION LEVEL ON 
RECEPTOR AGGREGATION AND FUNCTION 
 
 
Luteinizing hormone receptors (LHR) are G protein-coupled receptors (GPCR) found 
primarily in female and male reproductive organs where they play a critical role in ovulation and 
sperm maturation, respectively, as well as maintenance of sex hormone production in both sexes. 
The role of oligomerization in LHR function is of considerable interest and not well understood.   
The oligomerization state of LHR has been suggested to have a significant role in signaling, 
desensitization and internalization of this receptor after activation by either luteinizing hormone 
(LH) or human chorionic gonadotropin (hCG) [2-8]. Overexpression of membrane proteins such 
as LHR may result in molecular crowding and may lead to increased protein oligomerization [10].  
We hypothesize that LHR are present in the plasma membrane as constitutive small clusters or, 
alternatively, exist as dimers or mixture of monomers and dimers in the absence of hormone and 
then undergo varying degrees of aggregation after binding hCG. These differences in LHR 
organization depend on expression levels of LHR which may, in turn, affects LHR activity.   In 
this project, we examined the effect of LHR expression levels on receptor oligomerization using 
polarized homo-transfer fluorescence resonance energy transfer (homo-FRET) methods to 
evaluate receptor interactions in cell lines stably expressing averages of 10,000 receptors per cell, 
32,000 receptors per cell, 123,000 receptors per cell or 560,000 receptors per cell.  In addition, we 
measured levels of cyclic adenosine monophosphate (cAMP), a second messenger involved in 
signal transduction which is produced in response to activation of LHR. This study demonstrated 
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that the oligomerization state of LHR depends on the expression level of LHR, i.e.  the number of 
receptors per cell or the concentration of LHR per unit area. Although LHR appear as in dimers or 
oligomers in the plasma membrane when receptor expression levels are low, it is clear that, with 
increased expression levels, LHR are found in larger structures exhibiting lower values for initial 
anisotropy. The effect of hCG binding on LHR was dependent on the expression level of receptors 
in the absence of bound hormone. The greatest effect of hCG occurred in cells expressing low 
numbers of LHR per cell where receptors were able to undergo further aggregation in response to 
hormone binding.  The effect of hCG on highly expressed LHR was negligible; LHR, when highly 
expressed, were already extensively aggregated and did not undergo measurable changes in their 
aggregation state. Deglycosylated human chorionic gonadotropin (DG-hCG) had modest effects 
on cells expressing comparatively few LHR per cell since these receptors were already present in 
small clusters. Depletion of plasma membrane cholesterol using MβCD caused a decrease in 
intracellular cAMP level accompanied by decrease in cluster size of LHR as expression level of 
LHR increased.   
Together these results are important to our understanding of the roles that the expression 
levels of LHR, the oligomerization state of LHR and the plasma membrane play in LHR function.  
The organization of lipids in the bulk membrane and in membrane microdomains affects the ability 
of LHR to signal as does protein density, particularly when receptor crowding has occurred.  These 
studies also suggest, more generally, that protein organization in the plasma membrane may 
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1.1. Introduction  
1.1.1. The G protein-coupled receptor superfamily 
GPCR, also known as seven transmembrane domain receptors, represent the largest family 
of membrane proteins in the mammalian genome [11, 12]. GPCR mediate cellular responses to 
diverse molecules such as hormones, neurotransmitters, peptides, tastants, odorants and other 
mediators [13]. The GPCR receptor superfamily contains about 800 members in humans [14-16]. 
GPCR are involved in the regulation of physiological processes and in transferring signals from 
cell exterior to the cell cytoplasm through common changes in the structure of their transmembrane 
domains [17]. Furthermore, GPCR have emerged as targets for the innovative drugs that are 
available today in clinical trials or that are under development for clinical applications [16, 18]. It 
estimated that 50% of clinically prescribed drugs are targeted to GPCR [19, 20]. Together, these 
reasons support the importance of studying GPCR structure and functional properties.  
Human GPCR can be classified into six families; rhodopsin, secretin, adhesion, glutamate, 
frizzled and taste receptors (T2R), based on sequence homology and phylogenetic analysis [15, 
21, 22]. They function as either peptide, carbohydrate, nucleotide, amino acid, neurotransmitter, 
ion channels, protein or lipid receptors, based on their endogenous ligand type [16]. The rhodopsin 
subfamily is the largest and most diverse group of GPCR [15, 21].  
In general, the life cycle of GPCR includes synthesis in the nucleus, modifications in the 
endoplasmic reticulum, maturation in the Golgi Apparatus, delivery and insertion into the plasma 
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membrane. Upon ligand interaction and activation, signal transduction and then internalization is 
followed by recycling of GPCR back to the membrane or destruction through lysosomes [17]. 
Structurally, all the GPCR are composed of a single polypeptide chain with seven 
hydrophobic transmembrane (7TM) α-helices, an extracellular N-terminus and a cytoplasmic C-
terminus ([13]; Figure 1). However, they exhibit variations in size, in the structure of extracellular 
and intercellular loops [15], in receptor life cycle, the site of interaction with ligands, in the cluster 
size of the GPCR before and after binding to ligand and in the mechanism of signal transduction 
[17, 21]. 
As their name implies, GPCR interact with heterotrimeric G proteins. G proteins are 
members of the GTP-binding proteins family and have the ability to bind guanosine triphosphate 
(GTP) and guanosine diphosphate (GDP). A heterotrimeric G protein consists of three subunits α, 
β and γ. At least 16 different types of α subunits, 5 β subunits and 11 γ subunits in mammalian 
tissues have been identified in mammalian tissues. Each subunit leads to activation of different 
effectors downstream. Collectively, in an inactive state, heterotrimeric G proteins exist as a 
complex of α, β and γ subunits in which GDP is bound to α subunit at its guanine nucleotide 
binding site (Figure 2A). When in an active state, GPCR have undergone a conformational change 
that drives exchange of GDP for GTP. This GDP-GTP exchange also results in the dissociation of 
the heterotrimeric G protein from its GPCR and separation of the G protein trimer into an α subunit 
and the β-γ dimer. Activated α subunits can trigger a variety of downstream effectors depending 
on the type of α subunit that has been stimulated. For instance, αs activates adenylate cyclase (AC), 
the enzyme that convert adenosine triphosphate (ATP) to cAMP. cAMP, in turn, activates protein 
kinase A (PKA) which plays a role in phosphorylation and activation of downstream effectors [20, 
23], as shown in (Figure 2B). In contrast, αi is an inhibitor of AC. The αt subunit activates 
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phosphodiesterase (PDE) that catalyzes the breakdown of cyclic guanosine monophosphate 
(cGMP) to guanosine monophosphate (GMP) and leads to closure of a cGMP-dependent channel 
(Figure 2C). Phospholipase C (PLC) is activated by αq and breaks down to phospholipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) which stimulate protein 
kinase C (PKC) and cytosolic inositol triphosphate (IP3) leading to release of Ca+2. Ca+2 has roles 
in the downstream signaling cascade (Figure 2D). Activated β-γ subunits also have downstream 
effects on K+ channels, different proteins kinases or the activity of AC or PLC  [13, 21, 24].  
GPCR have been shown to function, after binding ligand, as monomers, dimers or 
oligomers. Interestingly, ligand binding to the receptor can induce formation of larger receptor 
complexes, smaller receptor complexes or have no effect on oligomerization, depending on the 
receptors in question [25]. Therefore, no generalizations can be made regarding the effect of ligand 
on the oligomerization state of GPCR and, in practice, it is important to study the effect of ligand 
on GPCR oligomerization for each individual receptor.  
The oligomerization state of GPCR is clearly an unresolved issue.  Emerging results 
indicate that GPCR can form dimers or oligomers in an early stage after biosynthesis and this will 
subsequently play an important role in receptor’s life cycle [26]. The concept of GPCR existence 
as dimers or oligomers may also be important in development of drugs targeting a specific receptor 
and its ability to undergo changes in its oligomerization [27].  
Despite the importance of receptor oligomerization and its relevance to clinical areas, there 
are only a small number of all GPCR that have been studied in detail. That promotes interest in 
new GPCR that might have potential as drugs targets to treat diseases that are not successfully 
treated using current drug therapies. LHR, which are the focus of studies described in this 
dissertation, are examples of GPCR that are classified as members of the rhodopsin family [28] 
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and, in addition, belong to the glycoprotein hormone receptor subfamily [2]. LHR are of both 
physiologic interest and clinical interest as discussed later in this dissertation.   
                         
 
        
 












Figure 2: Signal transduction pathways activated by GPCR.  Figure 2A shows an inactive receptor.  
No ligand is bound to the receptor and associated G proteins exist as a trimeric complex made up 
of an α, β and γ subunit. Figure 2B shows an active receptor in which the receptor has bound a 
ligand. αs has been released from the G protein and is activating adenylate cyclase. Figure 2C 
shows an active receptor which has activated αt which, in turn, activates PDE and hydrolyzes 
cGMP leading to closure of the cGMP-activated channel due to low concentrations of cGMP. 
Figure 2D shows an active receptor that activates αq which in turn activates PLC, converting PIP2 
to IP3 and DAG.  IP3 and DAG lead to release of Ca2+ and activation of PKC, respectively. 
Modified from W. Boron and E. Boulpaep [13].
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1.1.2. Biological action of the LHR 
LHR are critical to reproduction in both mammalian sexes [29]. The receptors are mainly 
present in gonadal cells including testicular Leydig cells and Sertoli cells in male and target cells 
in the female follicle and corpus luteum of the ovary [2, 28-31]. LHR are present more specifically 
in female in the theca, interstitial, and granulosa cells of the follicle [2] as shown in Figure 4A.  
LHR have also been identified in a number of non-gonadal cells such as cells from the prostate 
[32], breast [33], human uterus [4, 28], brain [2], human skin [34] and the adrenal cortex [33, 35, 
36] as shown in Figure 3. The role of LHR in these extragonadal tissues is unclear.  
The main biological role for the LHR in male puberty and the adult male is regulating the 
production and secretion of androgens that induce development of the secondary sex 
characteristics and stimulating sperm maturation [37, 38].  LHR in Leydig cells are also expressed 
during fetal life where they are critical to the development of the external male genitalia. The LHR 
in fetal Leydig cells are activated by maternal hCG. After puberty, testicular LHR are stimulated 
by pituitary LH [4, 38, 39]. 
 In female, LHR are found in theca cells and differentiated granulosa cells in the follicle 
and on luteal cells in the corpus luteum [38]. The LHR on granulosa and theca cells can promote 
the development of the follicle, enhance steroidogenesis and trigger ovulation ([4, 40]; Figure 
4A). Active LHR on luteal cells can promote ovulation and induce formation of corpus luteum 
(CL) which maintains the secretions of estrogen and progesterone. During female fetal 
development, LHR are not detectable. Expression begins, and only at very low levels, in neonates 
[38]. In puberty, a pituitary LH surge causes initiation of the first ovarian cycle and menstruation 
[41].  
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Pituitary LH and follicle stimulating hormone (FSH) are secreted from the anterior lobe of 
the pituitary gland in response to activation of gonadotrophs expressing gonadotropin releasing 
hormone receptors (GnRHR) by GnRH from the hypothalamus. LH and FSH promote maturation 
of the follicle in the ovary and increase production of estrogen [39, 42]. Due to high levels of 
estrogen made during folliculogenesis, a surge of LH released from the anterior pituitary promotes 
the rupture of the pre-ovulatory follicle and ovulation, i.e., release of the ovum [38, 39].  The 
follicle then forms a corpus luteum which maintains secretion of estrogen and progesterone, both 
of which stimulate endometrial growth.  If there is a pregnancy, hCG synthesized by 
syncytiotrophoblast cells of the placenta will sustain corpus luteum function [43]. However, the  
non-pregnant corpus luteum rapidly reduces its production of estrogens and progesterone and this 
leads to the shedding of the endometrium in menstruation [44]. It is notable that the number of 
LHR are not constant during the ovarian cycle in follicular or luteal cells, as shown in Table 1. 
Thus, the number of LHR may provide information about the health of the reproduction system. 
In summary, in males and normally cycling females, LHR bind LH, an anterior pituitary 
hormone, leading to synthesis of testosterone in males and hormone synthesis and ovulation in 
females. In addition, LHR bind hCG, a placental hormone, that helps maintain progesterone levels 
during the first trimester of pregnancy and stimulates fetal Leydig cell production of testosterone 
[45]. The normal function of the reproductive system in mammals is dependent on LHR and 
pulsatile release of LH, which act to regulate gonadal function in both sexes. Numerous mutations 
to inactivate or hyperactivate LHR have been identified and are associated with gonadal pathology 
related to reproductive disorders, endocrine-based diseases, metabolic changes or sex-dependent 
disease. Together these observations suggest that LHR plays an essential role in mammalian 




Table 1: hCG dissociation constants (KD), binding capacity (B) and the number of LHR in per 
granulosa or luteal cells from different stages of the estrous cycle. 
 
 
Data are presented as means ± SEM; means with different superscripts are significantly 
different (p<0.05) as shown by the analysis of variance followed by LSD (less significant 




          
  




        
 
Figure 4: Location and the biological role of LHR in the female and male reproductive systems.  
In females, LH is secreted from the anterior lobe of pituitary gland in response to an increase in 
estrogen levels (left panel). Active LHR regulate the maturation of follicle, rupture of the follicle 
to release an oocyte and maintain the corpus luteum which synthesizes and releases progesterone 
[47]. A cross section through the follicle shows LHR expressed in theca cells, granulosa cells, and 
interstitial cells [48]. In males (panel on right), LH is secreted from the anterior lobe of pituitary 
leading to synthesis of testosterone and spermatogenesis [49]. LHR are expressed in Leydig and 
Sertoli cells in the testis.  
A.1 B A.2 
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1.1.3.  Clinical and pathological significance of the LHR function  
Signal transduction by LHR in both mammalian sexes is essential for successful 
reproduction. LHR have natural-occurring mutations and polymorphisms that cause disorders in 
sexual development and defects in reproductive function [50, 51]. In males, inactivating mutations 
within specific LHR domains result in failure of testicular Leydig cells to differentiate, leading to 
Leydig cell hypoplasia (LCH) [52, 53].  Likewise, inactivating mutations in specific LHR domains 
in females result in amenorrhea and anovulation [54]. In contrast, activating mutations in specific 
LHR domains can cause the receptor to be constitutively activated leading to familial male-limited 
precocious puberty (FMPP; [50, 55]).  Clinically, patients with FMPP present with precocious 
puberty, Leydig cell hyperplasia, high levels of testosterone and low levels of gonadotropins [55].  
In addition to effects of LHR mutations on gonads, there are a number of human diseases 
related to LHR including Alzheimer’s disease (AD) [56-61], ovarian cancer [33, 62-64], breast 
cancer [65-68], prostate cancer [33, 69, 70], endometrial carcinomas [71-74], polycystic ovary 
syndrome [35, 40, 75, 76], uterus leiomyoma [33, 77], adrenocortical dysfunction [36], obesity 
[39] and Cushing’s syndrome [78, 79]. Each has been associated with over-expression of LHR and 
high secretion of LH. Furthermore, endometriosis is associated with low-expression of LHR [33, 
73].  
Evidence obtained from several studies suggests that dysregulation of LHR may affect the 
pathogenesis of AD. An in vivo study used transgenic knockout LHR mice to provide evidence 
that ablation of LHR significantly reduces the β-amyloid peptide (Aβ) load found in AD [56-60]. 
Ovarian cancer and other cancers are associated with over-expression of LHR.  This LHR 
overexpression and activation of LHR signaling may induce cell proliferation [80] leading to 
ovarian cancer or other cancers [33, 62-68]. Alternatively, ovarian cancer may be caused by 
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receptor overexpression leading to an increase in the cluster size of LHR. This may result in 
activated receptors, increased signaling by those receptors, increased cell proliferation and evasion 
of apoptosis by cancer cells. Thus, regulation of LHR expression may provide a new strategy for 
targeted cancer therapy. Finally, studies have found that skin changes in anovulatory and 
postmenopausal women can occur due to elevated of LH levels [34, 81, 82] which may result from 
an increase in expression of LHR in the skin of these women.  
Therefore, studying and understanding LHR expression level, oligomerization, and the 
function of LHR may provide new pharmacological approaches for use in treatment of endocrine-
related disorders. Furthermore, it is important to know the structure of intact LHR and to 
understand the human disorders related to LHR functions. Several mutations in LHR that naturally 
occur may lead to either loss or gain of function depend on how these mutations affect the 
conformation of receptors and LHR function [7, 31]. These mutations can lead to a lack of pubertal 
development and amenorrhea in females and impaired of spermatogenesis and infertility in males 
[2, 4, 39].  
1.1.4. Structure of LHR    
LHR are members of a superfamily of GPCR. LHR activate G proteins to initiate 
intracellular signaling as has been discussed above.  LHR also belong to the subfamily of the 
glycoprotein hormone receptors (GPHRs).  LHR bind glycoproteins hormones, LH and hCG, and 
are then activated [2, 28, 83].  
The mature human LHR consists of 699 amino acids with a molecular mass about 85,000 
Da [38, 84]. Human LHR are coded by a single copy gene that consists of 11 exons and 10 introns 
and is located on the short arm of chromosome 2 [85]. Exons 1-10 encode for extracellular domains 
and exon 11 encodes for the 7TM and the intercellular domain [4, 38, 76, 86]. 
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LHR are synthesized as a single polypeptide chain that can be divided functionally into 
three domains as shown in Figures 5 and 6 [2, 4, 28].  The large and divergent extracellular domain 
(ECD) is the glycosylated N-terminal domain with 340 amino acid residues. The ECD contains 
several leucine rich repeats (LRRs) flanked by cysteine-rich regions and a hinge region.  LH or 
hCG bind LHR at the ECD with high affinity [2, 45].  The ECD is believed to be involved in 
hormone binding and hormone specificity via LRRs that initiate the interaction with its 
corresponding hormone [5, 7, 45, 84, 86-89]. Also, the hinge region that is located in the ECD at 
the juncture with the TM domains is responsible for initial signal transduction as it links to the TM 
domains [2].  
A hinge region is coded by exon 10 and located in the ECD is crucial for differentiation of 
LHR signal transduction in response to hLH and hCG. The C-terminus of the hinge region sulfate 
tyrosine 331 is believed to be critical for  hLH binding stability [5, 38] and plays a key role in 
differentiation of signaling transduction between  hLH or hCG [5, 7]. Several studies suggested 
that deletion of exon 10 abolishes hLH, but not hCG, activity. Other studies have found distinct 
responses triggered by hLH or hCG binding to the extracellular domain [5, 7, 45, 86]. Although 
hLH and hCG bind the same receptor, they interact with different receptor sites and can cause 
different responses by target proteins in the intracellular pool.  
The second domain is highly conserved and contains 7TM α helices connected by three 
extracellular loops (ECLs) and three intracellular loops (ICLs) [2, 4, 83, 90]. Each α helical 
segment has about 25 to 35 amino acids residues [2, 38]. This second domain has cysteine residues 
in the first and second extracellular loop that play a role in stabilizing the structure of seven 
transmembrane α helices by forming an intramolecular disulfide bridge [28]. Conformational 
changes occurring in the 7TM, after being activated by hormone, translate to interactions between  
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LHR and G proteins on the intracellular surface and generate the signal [5, 91]. Mutations in the 
7TM segment cause LHR to be constitutively active, suggesting that it is essential for LHR activity 
[2].  
In addition, the 3rd and 6th transmembrane α helix and carboxyl portion of ICL2-3 may 
have effects on activation of G proteins in the intracellular side [38, 84]. However, ICL2 is believed 
to have a fundamental role in maintaining the LHR in an inactive conformation and block the 
signaling cascade [4]. Conformational changes occurring in 7TM after being activated by hormone 
lead to interactions between receptors and G protein on the intracellular membrane surface and 
generates the signaling [5, 91].   
The third domain is an intracellular C-terminal cytoplasmic tail (ICD) with 70 amino acids 
that initiates downstream signaling [2, 83]. This domain is the most divergent among the three 
domains and plays an important role in regulating the trafficking of receptors from endoplasmic 
reticulum to plasma membrane as well as receptor internalization [2]. It contains several threonines 
and serines that can be phosphorylated by PKA in the intracellular pool [28, 38]. The intracellular 
C-terminal region together with intracellular loops interacts with G proteins when LHR is activated 




Figure 5: Amino acid sequence of human LHR.  Different portions of the LHR are indicated, 
including the cysteine-rich N-terminus of the LRR and the hinge region in the extracellular 
domain.  Also shown are the seven transmembrane helices connected by 3 intracellular loops and 





Figure 6: Structure of hLHR showing three domains. The large extracellular domain is a 
glycosylated N-terminal domain which contains the site for ligand binding. The transmembrane 
domain spans the phospholipid bilayer with seven segments connected by three extracellular loops 
and three intracellular loops. The intracellular domain is a C-terminal cytoplasmic tail which is 









1.1.2. Human LH (hLH) and hCG  
LHR are target receptors for the pituitary-produced hormone LH  and a placenta-secreted 
hormone hCG [4, 94]. Both hormones are members of the glycoprotein hormone family and bind 
with high affinity to LHR found in the plasma membrane of target tissue cells ([95, 96]; Figure 
8A). Human LH (hLH) released during and after female puberty helps to convert androgens 
produced by theca cells in the follicle to estradiol.  Estradiol plays a role in regulating the 
development of secondary sex characteristics in females as well as follicular development in 
preparation for ovulation. After fertilization, LHR bind hCG, a placental hormone, rather than hLH 
[13, 24, 38, 80, 95]. The maternal placental hCG produced during male fetal development plays a 
role in induction of androgen synthesis that, in turn, induces differentiation of the external male 
genitalia. In human males, hLH from the anterior pituitary stimulates testosterone production 
which increases during puberty and post-puberty [13, 39, 97, 98]. 
hCG has a molecular weight of 57,000 Da [24] and consists of an α-subunit and β-subunit 
which are connected together by noncovalent interactions [24]. The α-subunit has 92 amino acids 
and contains five disulfide bridges and two N-linked carbohydrate sites [99, 100] that are coded 
for by one gene located on chromosome 6 [24]. The β-subunit has 121 amino acids and contains 
six disulfide bridges, two N-linked carbohydrate sites, and four O-linked carbohydrate sites [99, 
100] as shown in Figure 7. β-subunit is coded by six genes located in chromosome 19. The 
additional O-linked carbohydrate sites on hCG are present on the additional 24 amino acids found 
in hCG as compared to LH. Thus hCG has a larger molecular weight and additional carbohydrates 
when compared to hLH ([7, 24, 86, 96]: Figure 8B). hLH has a molecular weight of 28,500 Da 
[24], the same α-subunit found in hCG and coded for by a gene located on chromosome 6, and a 
β-subunit coded by a single gene located on chromosome 19 [24, 101]. 
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hLH and hCG are heterodimeric glycoproteins consisting of a species-specific common α-
subunit non-covalently associated with a unique β-subunit that is stabilized by a β cysteine loop 
that forms a “seatbelt” around the two subunits [5, 28]. The β-subunit defines the hormone’s 
individual biological properties. Both subunits, α and β, are required for full biological function 
[2]. Due to difference in the structures of hLH and hCG, LHR can qualitative discriminate between 
hLH and hCG through differences in hormone interactions with LHR [5, 95]. For instance, hLH 
has more hydrogen bond donors than hCG for interaction with sulfate tyrosine 331 in the hinge 
region of LHR [5]. Furthermore, it has believed that hLH and hCG can induce different signaling 
pathways in which hCG can activate the cAMP pathway to a greater extent than hLH, while hLH 
preferentially activates extracellular signal-regulated kinases (ERK) and protein kinase B (PKB) 
pathways [6, 94, 95, 102, 103]. In addition, studies suggest that hLH induces only cis-activation 
of LHR in vitro [5, 7, 45, 86] and induces cis-activation and trans-activation in vivo [104, 105] 
while hCG induces cis-activation and trans-activation of the receptor both in vivo and in vitro [5-
7, 45, 86, 106-109]. Moreover hLH and hCG differ in their half-life, 60-120 minutes for hLH and 
several hours for hCG [95, 110], probably due to the extra carbohydrates on hCG. Taken together, 
the LHR-mediated signaling mechanisms may change from signaling pathways used during the 
ovarian cycle to be signaling pathways used during pregnancy. 
In addition to structural differences in amino acid sequences, carbohydrates on both 
hormones are necessary for biological functions and hepatic clearance of the hormone from the 
body [111-113]. Most  of the carbohydrates can be removed from hCG to generate DG-hCG [112] 
which can bind LHR with the same high affinity as hCG but with little or no function [114-116]. 
This antagonist has been found in serum from patients with chronic renal failure disease with 
accompanying hypogonadism [114]. 
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In this study, hCG has been used for several reasons. Relative to LH, hCG has extra amino 
acids and these additional amino acids are believed to contribute to hCG association with LHR for 
longer times [4, 111, 117]. hCG binding to LHR appears to produce a larger molecular weight 
complex with multiple copies of the receptor. This leads to slower rotational diffusion rates for 
hCG-occupied receptors compared to LH-occupied receptors [116, 118] and higher levels of 
energy transfer between wild type LHR [118]. On a more practical level, hCG is more abundant, 
less expensive, more stable, has a longer half-life and is more readily available than hLH [38, 95, 
111]. Finally, hCG is more active in terms of cAMP production than is hLH [6, 94, 95, 102, 119].  
In summary, hLH and hCG have similar properties with respect to receptor binding and 
share a common α-subunit. Both hormones are important for reproduction in females.  They do, 
however, differ in their β-subunits and this difference may causes activation of different signaling 
pathways (Gs  versus Gq) through different mechanism mode of receptor interactions, cis-activation 
versus trans-activation, and different physiological responses [5-7, 45, 86, 117]. Cis activation 





Figure 7: Amino acid sequence of the common a-subunit and the unique b-subunit of hGC and 
hLH. hCG has additional amino acids that are believed to account for differences in hCG 









Figure 8: Interactions between LHR and hCG. Panel A is a sketch of hLHR interacting with hCG 
through the receptor’s LRR domain and hinge region. Panel B is a homology model showing the 
















1.1.3. DG-hCG is an hCG antagonist 
Human CG contains an α-subunit with five disulfide bonds and two asparagine N-linked 
carbohydrate chains and a β-subunit with six disulfide bonds, two asparagine N-linked 
carbohydrate chains, and four O-linked oligosaccharide chains [122]. About 30% of hCG’s 
molecular weight is due to glycosylation [112]. The carbohydrates are essential for biological 
function and control the rate of hepatic clearance from the body [111-113]. Approximately 85% 
of the carbohydrates can be removed from hCG by treating hCG with hydrogen fluoride (HF) for 
3 hours.  The deglycosylated molecule is referred to as DG-hCG [112, 123].  
If the subunits of DG-hCG are examined in more detail, it appears that HF removes about 
80% of carbohydrate from the α-subunit and 66% of carbohydrate from the β-subunit [112]. 
Alternatively, trifluoromethanesulfonic acid (TFMS) can be used for deglycosylation of hCG as 
has been done by Dr. George Bousfield at Wichita State University who prepared the DG-hCG 
used in this study [124, 125]. Alternatively, carbohydrate attachment sites, N-linked carbohydrate 
chains on either α-subunits or β-subunits, or O-linked carbohydrate chains, can be achieved by 
introducing mutations in the subunit genes [126, 127].  
DG-hCG binds LHR with the same affinity as hCG, as shown  in the binding affinity assay 
in Figure 9A, but has impaired ability to stimulate cAMP (Figure 9B; [112, 114, 122, 123, 127-
129]). Studies suggest that the carbohydrates removed from DG-hCG may, when present on intact 
hCG, interact with one or more “lectin-like” binding sites that are present on membrane sites near 
LHR causing activation of receptors and signaling via cAMP [112, 127]. Alternatively, there may 
be lectin-like binding sites present on LHR itself that interact with hCG’s carbohydrates [127]. A 
third possibility is that carbohydrates on the β subunits may bind LHR and, via an unknown 
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mechanism, trigger production of cAMP [5]. In general, the question of how hCG’s carbohydrates 
contribute to the function of LHR has not yet been answered.   
DG-hCG causes a decrease in the ability of LHR to activate AC in a dose-dependent 
manner; in the presence of DG-hCG, cAMP production in response to hCG was impaired while 
the production of cAMP by forskolin activation of adenylate cyclase was not inhibited. Pre-
incubation of LHR with DG-hCG prevents activation of the receptors by hCG for at least 46 h 
suggesting that binding of DG-hCG with LHR is slowly reversed [127]. Studies using human and 
monkey ovarian tissues, luteal cells, or granulosa cells treated with DG-hCG found some effect of 
DG-hCG on cAMP production and steroid production [130, 131]. However, it has been reported 
that DG-hCG can reduce production of cAMP in the presence of hCG or hLH  but not inhibit 
testosterone production to the same extent [128]. Interestingly, DG-hCG does not interfere with 
steroidogenesis in the presence of hCG [132, 133] although the mechanism for this lack of response 
is unknown; a low concentration of DG-hCG, an abbreviated incubation time, and the presence of 
either hCG or hLH may account for this lack of effect.   
There remains interest in DG-hCG’s properties as an LH/hCG antagonist.  Although 
several antagonists have been designed to block LHR activity and reduce the progression of certain 
LHR-associated cancers [134], DG-hCG may be a better antagonist since it exists naturally.  DG-
hCG has been found in serum from male patients with chronic renal failure disease who were 
suffering with hypogonadism  [114]. LHR function is inhibited by DG-hCG with no production of 
cAMP and impaired testosterone production [114, 135, 136], both attributed directly to the 





Figure 9: LHR binding and cAMP production in response to DG-hCG. Panel A shows that 
displacement of II25-hCG by hCG and DG-hCG were equally effective. Panel B shows dose-










1.1.4. Signal transduction by LHR 
LHR can be activated by high affinity binding of hLH or hCG although these hormones 
interact differently with the extracellular domain of LHR.  The segment of hinge region that is 
encoded by exon 10 is particularly important in signaling by hLH [5, 7, 38, 86]. This region creates 
a non-specific spacer element that adjusts the position of the sulfated tyrosine 331 residue in the 
receptor to favor hydrogen-bound interactions with hLH.  Interactions between hCG and LHR also 
depend on this region encoded by exon 10 region which serves as a structural interface with hCG. 
If exon 10 is deleted, interactions with the adjacent helix can compensate [5] as shown in Figure 
10.  
Once the hormone binds to LHR, conformational changes in the 7TM of the LHR are 
induced leading to either cis-activation or trans-activation. These distinct mechanisms lead to 
different signaling pathways. In cis-activation, either hLH or hCG binds to an extracellular domain 
of LHR leading to activation of the same LHR that originally bound hormone [6, 7, 106-109]. In 
trans-activation, the ligand, hCG in in vitro experiments [6, 7, 106-109] or hLH in in vivo 
experiments [104, 105], binds to the extracellular domain of first LHR and then causes trans-
activation of an adjacent receptor that has not bound ligand [6, 107-109] (Figure 11). Studies using 
mutated hLHR which are unable to signal (LHRcAMP−), combined with muted hLHR that cannot 
bind hormone, (LHRLH−) have suggested that hLH can activate hLHR only through cis-activation. 
In contrast, hCG has ability to initiate both cis-activation and trans-activation [6, 7, 106-109]. In 
contrast, studies using male mice with knockout LHR and co-expressing the two mutant LHR, 
LHRcAMP−and LHR LH−, demonstrated complete rescue, i.e., the wild-type phenotype, in the 
presence of high levels of LH. This could happen only through receptor trans-activation and 
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provides support for this mechanism of receptor activation by both hLH and hCG [104, 105, 
137]. 
Once activated, LHR triggers the activation of a G protein, a heterotrimeric protein 
consisting of α, β and γ subunits.  The G protein is associated with the cytoplasmic C-terminus of 
the LHR.  LHR independently activate two distinct G protein-dependent signaling pathways via 
Gs and Gq. For both G proteins, the activated α subunit undergoes an allosteric change and swaps 
GTP for GDP leading to the dissociation of α subunit from the membrane-anchored βγ subunits.  
It then binds to an effector downstream, either AC for Gs  or PLC for Gq (Figure 12)  
In the GS-activated pathway, the α subunit activates AC which converts ATP to cAMP [5, 
38, 45, 138]. cAMP then activates PKA and an exchange protein directly activated by cAMP, 
EPAC. This results in the phosphorylation of transcription factors such as a cAMP-response 
element-binding protein (CREB) which regulates expression of target genes like P38 mitogen-
activated protein kinases (P38 MAPK) which is responsible for a pro-apoptotic event. In addition, 
CREB can activate the steroidogenic acute regulatory protein (STAR) gene to produce the STAR 
protein. STAR regulates steroidogenesis [4, 45, 80, 84, 94, 102, 139] by controlling the transport 
of cholesterol to the mitochondria for synthesis of steroid hormones. The first enzyme participating 
in steroidogenesis is a cytochrome P450 cholesterol side chain cleavage enzyme (P450scc) needed 
for synthesis of pregnenolone and further modifications to produce steroid hormones [13, 139].  
Although the Gs pathway is the major signaling cascade regulating steroidogenesis, 
additional pathways are involved in steroidogenesis such as the Gq pathway [5, 38, 140, 141].  In 
this pathway, the α subunit activates PLC leading to formation of DAG and cytosolic IP3 from 
PIP2. IP3 triggers release of Ca+2 from the endoplasmic reticulum and activates rapamycin 
complex 1 (mTORC1) which is involved in proliferation and cell survival [2, 4]. An increase in 
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the Ca+2 in the cytoplasm from intracellular stores affects potassium channels and activity of a 
variety of target proteins that play important roles in steroidogenesis including progesterone 
synthesis [111, 139, 142].  DAG in turn activates PKC, protein kinase B (PKB) and Akt signaling 
pathways that have roles in regulating cell proliferation and cell survival and induce several 
enzymes involved in steroid synthesis [2, 4, 39, 141, 143-145].  
Activated LHR can participate in crosstalk with other receptors such as epidermal growth 
factor receptors (EGFRs) or insulin-like growth factor 1 receptors (IGF-I) [146], both tyrosine 
kinase receptors. Activation of tyrosine kinase receptors leads to activation of Rap/Raf/Ras 
proteins that, in turn, activate extracellular signal-regulated kinases 1 and 2 (ERK1/2) to trigger 
phosphorylation and activation of transcription factors involved in cell cycle regulation, cumulus 
expansion, and cell growth.  In addition, transcription factors involved in tumor progression, 
proliferation, and steroidogenesis may also be activated by cAMP and PKC [2, 147]. Activated 
ERK can activate EPAC which triggers an anti-apoptotic response [4, 80, 102, 139, 143]. 
Activation of the ERK cascade might involve other signaling molecules such as the Src family of 
kinases (SFKs) that induce expression of genes important in regulating Leydig cell and corpus 
luteum function [80]. IGF-I has been shown to increase the expression level of LHR mRNA [139]. 
Collectively, multiple pathways interact with each other to stimulate steroid biosynthesis in LHR-
dependent pathways.  
LHR also undergo receptor desensitization following hormone binding to the receptor and 
activation. Phosphorylated hLHR causes activation of an Arf nucleotide binding site opener 
(ARNO) which in turn activates ADP ribosylation factor 6 (ARF6), a guanine nucleotide exchange 
factor, via exchange of GDP by GTP. Active ARF6 promotes the disassociation of β-arrestin from 
a membrane docking site in ARF6.  Arrestin is then available to bind to active LHR to terminate 
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their activity. Subsequently, hydrolysis of GTP to GDP in Gα leads to inactivation of the G protein 
and re-association of α with the γβ dimer to restore the G-protein heterotrimer [84, 148, 149].  β-
arrestin is directly activated by ERK1/2 slowly [4].  Interestingly, recruitment of β-arrestin to 
inactivated receptors is detrimental to expression levels of the receptors. A decrease in receptor 
density in cell membranes can regulate and induce β-arrestin-dependent signaling [150]  
suggesting that there is a balance between active and inactive receptors that depends on receptor 
numbers. However, other studies have suggested that phosphorylation of LHR is not required for 
desensitization [151-153]. Therefore, LHR desensitization is expected to use other mechanisms 
such as interaction between LHR and β-arrestins without requiring LHR phosphorylation [154] In 
alternatively, desensitization of LHR have been reported to be dependent upon GTP mechanisms 
[155] and  studies using mutated LHR in candidate amino acids involved in phosphorylation of 
LHR, have found that the phosphorylation is needed but not sufficient for desensitization of LHR  
[156, 157] 
As have been described, there are slight differences between hLH and hCG structures that 
lead to differences in association with hLHR and which may affect LHR activation and signaling 
pathways.  hCG can activate Gαs to produce more intracellular cAMP and pro-apoptotic potential 
while hLH can activate Gαq. In addition, hLH appears responsible for crosstalk with tyrosine 
kinase receptors leading to more ERK and PKB production and greater anti-apoptotic potential [6, 
94, 95, 102, 119, 143]. Signaling effects of LH and hCG are complicated by hormone effects on 
cis-activation and trans-activation of hLHR in vitro [5, 7, 45, 86] which can lead to different 









Figure 10: Sketches of differences in the interactions of hLH and hCG with the hinge region of 
LHR.  Panel A shows that the wild-type LHR has an exon 10-derived helix that shifts the s-Tyr331 
to an appropriate position near an adjacent helix to interact with hLH.  For hCG, the exon 10-
derived helix functions as a structural interface. Panel B shows that deletion of exon 10 in LHR 
causes the adjacent helix to move to an appropriate position to interact with hCG.  There is an 




A. LHR (complete hinge region)                                  B. LHR deletion Exon 10  






Figure 11: Schematic representation of cis-activation and trans-activation of LHR.  Adapted from 

















Figure 12: Signaling pathways regulated by activation of LHR.  AC can be activated by LHR to 
induce its downstream pathway. Similarly, PLC can be activated by LHR to induce its downstream 
pathway. Also, LHR can participate in crosstalk with other receptors such as EGFR and IGFR, 
activating their respective downstream signaling pathways [139]. 
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1.1.5. Crowding, oligomerization of LHR and receptor activity 
The oligomerization of membrane proteins increases in response to increasing molecule 
crowding [149, 158]. In addition, the activation of receptors also occurs in response to increased 
receptor density in cell membranes [7, 150, 159]. Macromolecular crowding is considered to be a 
high concentration of proteins or high density of proteins in a given area.  High protein 
concentrations in membranes tends drive formation of oligomeric structures or nonfunctional 
aggregates [160].  
Crowding of molecules strongly depends on the relative number of molecules, size of 
molecules, shape of molecules and dilution of molecular reactants [158, 160]. Molecular crowding 
is important because of its effects on cell membrane molecular structures including folding, shape, 
conformational stability, molecule diffusion and behavior including binding of other molecules, 
enzymatic activity, and downstream signaling. Thus, molecular crowding plays an important role 
in signal transduction and cell function [119, 149, 158-160].  It has been found that many proteins 
can become activated in the oligomerized state.  Other studies found that many proteins exist as 
dimers or oligomers even when they are inactive. Thus, the oligomerization state of proteins and 
their activity can be affected by crowded environments with variable effects on protein activation 
[119, 149, 158-160]. 
A crowded environment can affect the aggregation of LHR and may have effects on LHR 
activity [119, 149, 150, 159, 161]. The density of follicle stimulating hormone receptor (FSHR), a 
structurally-related glycoprotein receptor, in the plasma membrane can control receptor signal 
transduction including cAMP production in response to hormone. However, a mutant FSHR 
(A189Va) mimics the hormone-response of wild type FSHRs when expressed at low levels of 
receptors (Figure 13). cAMP production can be rescued when A189Va-mutated FSHRs are 
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expressed in higher numbers [150]. Therefore, controlling the expression level of receptors has 
potential use as a therapeutic approach to treat this type of mutation. Furthermore, when cells are 
co-transfected with LHR that are signaling-deficient (LHR-cAMP) and binding-deficient (LHR-LH), 
increased expression levels of these mutant LHR in plasma membranes increases intracellular 
levels of cAMP in the presence of hormone [7]. Increasing the expression levels of wild type LHR 
from 600 to 125,000 LHR/cell and co-expressing these wild type receptors with mutant receptors 
(LHR-cAMP, LHR-LH) leads to increased cAMP production in response to hormone in an expression-
dependent manner (Figure 14; [159]).   
Therefore, it is necessary to consider the potential impacts of molecular crowding on 
oligomerization state of proteins when evaluating receptor or protein activation, particularly for 
those proteins that naturally exist at low concentrations such as LHR [46, 160]. The overexpression 
of proteins can lead to a crowded environment and increase protein oligomerization.  As an 
example, neurokinin-1 receptors overexpressed in cells were present in larger clusters when 
compared to cluster sizes in cells expressing physiological levels of neurokinin-1 receptors [10].  
These various effects of receptor crowding suggest that it is important to carry out 
experiments under physiological conditions with an expression levels of proteins that are similar 
to naturally-occurring receptor numbers. Interestingly, when proteins are expressed in live cells 
via transient transfection processes, there is a higher chance of obtaining higher expression levels 
[149] and concerns about changes in protein structure, oligomerization and function. 
 In conclusion, the crowded environment of proteins including LHR may lead to effects on 
protein structure, protein oligomerization and activity. Furthermore, aggregation of LHR may 
result from high expression levels. This may contribute to many human diseases such as AD [56-
61], ovarian cancer [33, 62-64], breast cancer [65-68], prostate cancer [33, 69, 70, 162], 
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endometrial carcinomas [71-74], polycystic ovary syndrome [35, 40, 75, 76], uterus leiomyoma 
[33, 77], adrenocortical dysfunction[36], obesity [39] and Cushing’s syndrome [78, 79].  One goal 
of studies described in this dissertation is to provide a foundation for new pharmacological 






Figure 13: Binding assay and cAMP assay for WT FSHR and mutant FSHR (A189V). Panel A 
shows results of a binding assay to determine the total number of FSHR expressed. Panel B shows 
results of expressing low levels of wild type FSHR or mutant FSHR,  Both receptors failed to 












Figure 14: cAMP level induced by hCG binding to cell populations expressing increasing numbers 
of receptors per cell. Intracellular levels of cAMP increased as the average numbers of wild type 







1.1.6. The role of cholesterol in LHR function 
Cholesterol is major component of eukaryotic plasma membranes and plays an essential 
role in membrane organization, dynamics and function [1, 163, 164]. Cholesterol is a lipid that 
contains four fused hydrocarbon rings with a flexible hydrocarbon tail. The tail interacts with the 
plasma membrane as does the hydroxyl group on the first fused ring ([1, 165]; Figure 15). 
Cholesterol, together with sphingolipids, is distributed in plasma membrane domains called lipid 
raft microdomains [164]. Membrane cholesterol also modulates the function, dynamics, and 
stability of many membrane proteins [1, 166-173]. Although the depletion of membrane 
cholesterol has detrimental effects on many proteins [1, 166-168, 174, 175], the presence of 
cholesterol inhibits the function of rhodopsin [176]. Therefore, cholesterol-mediated effects in 
protein function appear to be protein specific. 
Despite the importance of membrane cholesterol in protein function, the mechanistic basis 
for cholesterol’s effects is still under investigation.  Recent studies have shown that membrane 
cholesterol can directly or indirectly interact with membrane proteins [1, 164, 172, 177, 178]. 
Membrane cholesterol may interact directly with a cholesterol binding motif in membrane 
proteins. This interaction could induce a conformational change, help to stimulate oligomerization, 
or improve the stability of the membrane protein. Specific cholesterol binding motifs in different 
membrane proteins are of intense interest [179, 180]. Conversely, membrane cholesterol may 
indirectly affect a membrane protein by altering the physical properties of lipid membranes. 
The localization of LHR in rafts containing cholesterol may be important in LHR function.  
Functional LHR treated with hCG and constitutively active LHR exist in lipid rafts while non-
functional LHR are found in the bulk membrane [181, 182]. These studies indicated that membrane 
cholesterol and raft domains are important in LHR signal transduction and that cholesterol 
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depletion using methyl-β-cyclodextrin (MβCD) [183-186] leads to a decrease in intracellular 
cAMP [181]. Studies of adenosine A2A receptors have shown that cholesterol depletion inhibits 
the activity of these receptors and reduces cAMP production [187]. In addition, MβCD reduces 
the cluster size of the serotonin1A receptors and decreases signal transduction in response to ligand 
[166, 171, 173, 188]. Similarly, reducing membrane cholesterol leads to a decrease in the cluster 
size of  µ-opioid receptors and glycosyl phosphatidyl inositol (GPI) anchored proteins [189] and 
decreased signaling transduction [190]. In this study, the effect of expression level of receptors on 
the degree of change in LHR oligomerization, on receptor activity upon depletion of plasma 















































Figure 15: Model of lipid organization in lipid raft microdomains including cholesterol’s 









2.1. Measuring the size of protein clusters 
2.1.1. Oligomerization of LHR  
The view that most GPCR, including LHR, function as monomers is changing.  More 
recent studies of GPCR support the concept that receptor oligomerization is a fundamental process 
required for receptor activation [191]. LHR, in particular, have been found clustered as dimers or 
oligomers in the plasma membrane using techniques based on fluorescence resonance energy 
transfer (homo-FRET, BRET) [149, 192], fluorescence cross-correlation spectroscopy (FCCS) [7] 
dual-color photoactivatable dyes and localization microscopy (PD-PALM) [140] or co-
immunoprecipitation [193].  
Activated LHR, after binding to hLH or hCG, are involved in two distinct mechanisms for 
receptor activation, cis-activation and trans-activation [5-7, 45, 86, 117]. Both activation 
mechanisms are accompanied by receptor clustering in the plasma membrane (Figure 16). 
Oligomerization of LHR in the plasma membrane after activation has been shown using 
fluorescence photobleaching recovery (FPR) [8, 194], techniques based on florescence resonance 
energy transfer such as homo-FRET and hetero-FRET [3, 8, 118, 149, 182], electron microscopy 
studies with ferritin-labeled LH [195] and co-immunoprecipitation of epitope-tagged LHR [193]. 
It has been found that the cluster size of hLHR increases upon hormone binding in a concentration-
dependent manner [196]. The clustering of LHR is suggested to play an important role in signaling, 
desensitization and internalization of LHR after activation by hormone [2-8]. 
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 Dimerization or oligomerization of LHR may also occur, to some extent, early in receptor 
biosynthesis in the endoplasmic reticulum and is unrelated to receptor activation [2, 27, 192].  As 
a result, inactive LHR may be inserted in the plasma membrane as dimers.  Studies using mutated 
hLHR that do not signal (LHR cAMP−) combined with mutated hLHR that do not bind hormone 
(LHR LH−) have shown that trans-activation and the association between these muted receptors 
occurs in the plasma membrane [104, 106, 137].  
A number of biochemical and biophysical methodologies have been used during the last 
decade to study the cluster size of proteins in general and LHR in particular. The most common 
biochemical approaches that have been used to study oligomerization of LHR are co-
immunoprecipitation and SDS-PAGE with cross-linking [3, 66, 104, 109, 193, 197, 198]. The 
drawback to these approaches is that they require lysis of the cell and solubilizing the cell 
membrane which can lead to artificial protein-protein interactions or destroy existing interactions.  
In addition, these methods are not suited to monitoring protein oligomerization in live cells. On 
the other hand, common biophysical approaches that have been used to study oligomerization in 
live cells include FRP [8, 194], BRET [192, 199], hetero-FRET, FCCS [7, 200, 201] and 
bimolecular fluorescence complementation (BiFC) [202, 203]. Nevertheless, each of these 
methods has drawbacks. For instance BRET requires long integration time and the emission 
intensity is very low [17, 204]. FCCS does not provide spatial information so it cannot distinguish 
signals from the plasma membrane from those of intracellular molecules and is limited by 
interactions where diffusion is rapid.  FCCS is not ideal for studying membrane proteins that have 
slow diffusion and do not transit the interrogation volume frequently enough to provide reliable 
fluctuations over experimental times [204]. In hetero-FRET, it is hard to control the expression 
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level of two fluorophores at equivalent levels [205]. BiFC cannot distinguish between dimer and 
oligomer formation [202, 203]. 
In this study, homo-FRET [149, 196] was used to evaluate the cluster size of LHR on the 
nanometer scale (Table 4-6 ). Homo-FRET measurements are the best choice for quantitative 
assays because they can measure clusters of proteins in live cells, are sensitive to changes in 
molecule formation or molecule abundance, have high spatial resolution, and are convenient for 
use with commercial florescence microscopes with FRET accessories and software [19].  
Observation of cluster size of proteins within live cells will greatly help is better understand 










             
 
Figure 16: Schematic representation of cis-activation and trans-activation leading to LHR 
clustering. This cluster of LHR dimers or oligomers exists in the plasma membrane of cells as 







2.1.2. Fluorescence Resonance Energy Transfer (FRET) 
Fluorescence resonance energy transfer (FRET), first described by Theodor Förster in 
1946, is a physical phenomenon in which an excited donor fluorophore non-radiatively transfers 
energy to a neighboring acceptor fluorophore. Subsequently the acceptor fluorophore emits its 
characteristic fluorescence ([206], Figure 17).  FRET has become a popular technique used in cell 
biology, biochemistry and biophysics for studying molecular aggregation, interactions, 
conformation and dynamics in live cells [171, 207-211].   
There are three requirements for FRET. First, the emission spectrum of the donor should 
overlap with the absorption spectrum of the acceptor. Second, the emission of donor and 
absorption of acceptor transition dipole moments are not perpendicularly oriented. Third, the donor 
and acceptor should be close together. FRET can be an accurate measurement of molecular 
proximity at distances between 2-10 nm (10–100 Å) and reaches the highest efficiency when the 
donor and acceptor are positioned within this range [19, 206, 207, 210]. The Förster distance r0 is 
the distance at which 50% the excitation energy of the donor is transferred to the acceptor. If the 
distance between donor and acceptor is more than 10 nm, FRET does not occur. The efficiency of 
FRET (E) as showed in Equation 1 is depends on the inverse sixth power of the intermolecular 
distance (r) between the donor and acceptor which FRET efficiency sensitive to small changes in 
distance [19, 212-216]. 
                                                 E=1/(1+r/ r0
6
)                                                                              (1)        
 
In general, there are two types of FRET. The first type of energy transfer is between 
different donor and acceptor molecules and is called hetero-FRET. In the second type, energy 
transfer occurs between identical molecules which is called homo-FRET. In hetero-FRET, the 
emission from donor is quenched and emission from the acceptor is enhanced so the efficiency of 
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FRET can be determined by measuring the donor/acceptor intensity ratio [161, 213]. Homo-FRET 
can be measured by steady state anisotropy or time-resolved fluorescence anisotropy [217-219].  
To evaluate FRET, confocal microscope or wide-field fluorescence microscope is used with a laser 
or an arc lamp source with appropriate filters as an excitation source [215, 217, 220, 221]. Both 
steady state anisotropy and time-resolved fluorescence anisotropy can detect the oligomerization 
state of proteins based on measuring the transfer between the fluorophores. Since only steady state 
anisotropy was used to detect the cluster size of LHR, it will be the only FRET method discussed 
here. 
 
2.1.3. Detection of homo-FRET using steady state anisotropy 
 Homo-FRET is a powerful tool that has been used to determine the aggregation state of 
proteins such as neurokinin-1 receptor, serotonin1A receptor [19, 171, 211], GPI [208, 217], 
EGFRs [197, 208, 215, 222, 223], band 3 protein [224], melittin [209], and herpes simplex virus 
(HSV-1), thymidine kinase (TK) [218] as well as other GPCR [208].  
Homo-FRET, also called polarized FRET, excites a single fluorophore with polarized light 
[225]. Homo-FRET, as illustrated in Figure 18, is based on energy transfer between two identical 
fluorescent molecules such as enhanced yellow fluorescent protein (eYFP). Fluorescent molecules 
appropriate for use in homo-FRET should have a small Stokes shift between their absorption and 
emission spectra peaks, significant overlap between the excitation and emission spectra as is the 
case for eYFP, high quantum yields and large extinction coefficients, (Table 2)  [19, 188, 204, 
209, 226]. Homo-FRET is accompanied by changes in the polarization of emitted fluorescence 
[225].  
Homo-FRET can be measured by steady state anisotropy which is evaluating the loss of 
the polarization of emitted fluorescence with respect to polarized excitation light [212, 217]. The 
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polarization of emitted fluorescence can be monitored by examining differences in polarization 
that occur. In steady-state anisotropy, as more energy is transferred between molecules, there is an 
accompanying increase in the depolarization of emission fluorescence. Steady-state anisotropy r 
is calculated from emitted fluorescence intensities Ivv and Ivh, parallel and perpendicular to the 




                                                                                      (2) 
where Ivv is the intensity of emission that is vertically oriented and Ivh is the intensity of emission 
that is horizontally oriented with respect to vertically polarized excitation light. Ivv and Ivh are 
measured in separate channels [161, 171, 215, 216, 220, 227] . The G factor (G) is a correction 
factor for different detection sensitivities of vertical and horizontal polarized fluorescence in the 
instrumental setup. It acts as a normalization factor to compensate for optical properties such as 
reflections from mirrors that may change the polarization angle of excitation light. In an ideal 
setup, G would be equal to 1 [215, 216, 220].  Methods used to determine the instrumental G factor 
are discussed in methods.  
Experimentally, a sample is illuminated with vertically polarized light and photo-selection 
occurs. Those fluorophores that are oriented parallel to the vertically polarized light are 
preferentially excited while fluorophores that have horizontally-oriented transition dipoles relative 
to vertically polarized light are not excited. The excited fluorophores that exist in this anisotropic 
distribution will transfer energy to randomly oriented nearby fluorophores. As a result, the emitted 
light will be partially depolarized because the emission dipoles are oriented randomly relative to 
the polarized excitation light (Figure 18). If there is no energy transfer between fluorophores 
because the distance between fluorophores is more than 10 nm, the emission will be polarized 
 47 
(Figure 18) [161, 217, 220, 227-229]. Anisotropy decreases as a result of transfer of energy 
between fluorophores.   
Anisotropy, however, can decrease by other means such as rotational movement of the 
fluorophore molecule which increases the depolarization of anisotropy [171, 207, 218].  To 
distinguish between the rotation effects and homo-FRET effects on fluorescence anisotropy, 
fluorescence anisotropy can be measured during progressive fluorescence photobleaching under 
conditions where steady state anisotropy can be recorded [171, 207, 208]. Basically, 
photobleaching effectively decreases the number of intact fluorophores in a cluster over time.  This 
leads to an increase in fluorescence anisotropy as the number of fluorophores available for energy 
transfer decreases. Important to these studies, which used eYFP as a fluorophore, is that rotational 
movement of the fluorophore molecule can be neglected. This is because the rotation correlation 
time of eYFP is - ~16 ns [230] which is slower than its fluorescence lifetime of .D ~3.5 ([171], 
Table 2). This means, in practice, that any observed depolarization of emission occur by 
transferring energy since the rotational movement of eYFP is very slow and can be ignored [171, 
208]. 
The steady state anisotropy or the degree of polarization has been demonstrated to be 
inversely proportional to the oligomerization state of fluorophores [209, 227].  The number of 
fluorophores in clusters can be revealed by comparing anisotropy of experimental data with a 




Figure 17: FRET diagram. The donor fluorophore is excited, i.e., reaches the S1 state, and then 
relaxes to the lowest excitation level. During relaxation, it transfers its energy to a neighboring 
fluorophore that serves as an energy acceptor. After that, the acceptor fluorophore drops back to 





Figure 18:  polarized light. lyreceptors excited with verticalshowing  FRET-rinciple of homoP 
Upper panel: In the case of no homo-FRET, receptors tagged with eYFP are separated by distances 
greater than 10nM and fluorescence emission is relatively polarized.  Middle and lower panels:  
When receptors are comparatively close together, there is transfer of energy between two like 
fluorophores.  This energy transfer results in depolarized fluorescence emission from the acceptor 
fluorophore and lower anisotropy values.  The depolarized fluorescence emission can be used to 
estimate the cluster size since depolarization is increased when the cluster size is increased, and 
homo-FRET has occurred.  Ivv is the intensity of emission that is vertically oriented and Ivh is the 







2.2. Measurement of intracellular cAMP  
2.2.1. Signal transduction and cAMP level are regulated by LHR 
cAMP is a ubiquitous second messenger that plays an important role in many cellular 
processes [231-233].  Increased cAMP levels in the cytoplasm are generated by activation of 
GPCR that lead, in turn, to activation of the Gαs subunit and AC, an enzyme that converts ATP to 
cAMP [5, 38, 45]. cAMP can trigger cellular responses through activation of effector proteins such 
as PKA and EPAC [4, 45, 80, 84, 94, 102, 139]. 
When LHR bind hLH or hCG, a signaling cascade is activated. Due the minor differences 
between the two hormones, the signaling pathways used will differ slightly.  hCG can activate Gαs 
which produces more intracellular cAMP than does hLH [6, 94, 95, 102, 119, 143]. Despite the 
differences, binding of either hormone leads to increases in intracellular cAMP  [5, 38, 45].  Thus, 
the increase in cAMP production in cells reflects receptor activity [234] and can be measured by 
biochemical and biophysical assays [94, 231, 232, 234]. 
 
2.2.2. Measuring of cAMP 
The traditional biochemical technique used to measure cAMP in vitro is radioimmunoassay 
(RIA), a method that has been available for decades. This technique requires lysis of cells to obtain 
a small amount of soluble cAMP. This cAMP can be quantified using cAMP antibodies and 125I-
labeled cAMP. The drawbacks to RIA and other biochemical techniques such as 
electrochemiluminescence immunoassays (ECLIA) and enzyme-linked immunosorbent assays 
(ELISA; [234]) is that information is obtained from many cells but cannot be obtained from a 
single cell. In addition, temporal changes in intracellular cAMP are difficult to measure [232, 233]. 
This has led to the development of methods using FRET-based sensors that provide information 
on cAMP levels in individual living cells with high spatial resolution [94, 231-236]. FRET-based 
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sensors have regulatory and catalytic subunits of a cAMP-dependent protein kinase, Epac, or a 
single cAMP-binding domain from a cyclic nucleotide-gated channel that has been fused to two 
fluorescent proteins used as donor and acceptor fluorophores.  FRET donor and acceptor pairs 
must have overlap between the emission spectrum of the donor and the absorption spectrum of the 
acceptor [231, 233, 236-238]. These FRET-based sensors can be transfected into a cell as, for 
example, Epac-based cAMP sensors, or do not require cell transfection as is the case for 
homogeneous time-resolved fluorescence (HTRF) assays available in kit from Cisbio [94, 202, 
235, 236, 239].  
Multiple studies have measured intracellular levels of cAMP in cells expressing LHR in 
response to hCG via RIA or ELISA assays that are commercially available [80, 86, 108, 159, 194, 
234].  More recent studies have used Epac-based cAMP sensors to measure cAMP in individual 
cells.  FRET-based sensors like the “indicator of cAMP using Epac” sensor (ICUE), the 
mTurquoise sensor, or a BRET-based cAMP sensor using YFP-Epac-RLuc (CAMYEL sensor), 
have been used to measure intracellular level of cAMP in cells expressing LHR that have been 
treated with hCG [94, 234, 236, 239-242]. 
 
2.2.3. ICUE3, a FRET-based cAMP sensor  
Several FRET-based sensors derived from Epac are called ICUE. They have been used to 
measure in real time cAMP in live cells [231, 236-238]. The ICUE3 molecule is targeted to the 
plasma membrane and provides dynamic detection of cAMP. ICUE3, illustrated in Figure 20, has 
a palmitoylation site from Lyn kinase for membrane targeting, allowing measurement of cAMP 
close to the plasma membrane.  ICUE3 has an N-terminally truncated Epac1 protein fused at its 
N-terminus with an enhanced cyan fluorescence protein (eCFP) donor and a circularly permuted 
Venus at lysine 194 of eYFP (cpV-L194) acceptor, an improved version of eYFP [231, 236, 243], 
 52 
(Table 2). In the absence of bound cAMP, ICUE3 folds so that the distance between eCFP and 
eYFP is 5 nm or less FRET occurs from the CFP to the eYFP moiety ([244]; Figure 19). In 
presence of cAMP, ICUE3 undergoes a conformation change resulting in separation of eCFP and 
eYFP and a decrease in FRET. Calculating the change in the emission intensity ratio of CFP to 





                          
 
Figure 19: Excitation and emission spectra of a CFP-YFP FRET pair in ICUE3. This figure shows 
donor (CFP) excitation and emission spectra and acceptor (YFP) excitation and emission spectra. 













Figure 20: ICUE3 structure and function.  Panel A illustrates the structure of ICUE3 which 
consists of Epac1 flanked by ECFP and cpV-L194.  When there is no cAMP, ICUE3 is folded in 
such a way to allow FRET to occur.  Upon binding cAMP, the ICUE3 undergoes a conformational 
change that results in a decrease in the FRET signal [236]. Panel B shows that upon binding cAMP, 


























































hetero-FRET eCFP-eYFP pair in 
ICUE3 
435 540 0.4 3 4.9 [205, 244, 245, 
247, 248] 
Table 2: Properties of fluorescent proteins used in these studies 
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2.3. Hypothesis 
When large numbers of LHR are expressed in individual cells, LHR exist in a crowded 
environment [119, 149, 150, 159, 161].  As discussed previously, an increase in expression of LHR 
may lead to increased protein density and drive oligomerization of these proteins [149, 160, 196]. 
Oligomerization of LHR, either in response to binding of hCG or over-expression of the receptor, 
increases intracellular levels of cAMP [7, 150, 159]. Many studies have found that hormone 
binding to LHR increases oligomerization of LHR [3, 5-7, 45, 86, 117, 149, 196] and increased 
intracellular levels of cAMP [80, 86, 94, 108, 159, 194, 234, 240, 241, 249]. Importantly, 
overexpression of LHR may induce molecular crowding that can lead to changes in proteins 
structure, protein oligomerization and protein function, all of which may lead to misinterpretation 
of experimental results. Therefore, it is essential to consider the potential effects of LHR 
expression levels, i.e., receptor number per cell, on the oligomerization state and activation of 
LHR. We hypothesize that, in unstimulated cells, the size and activity of LHR clusters have 
strong positive correlation with expression levels of LHR, as indicated by measured 
anisotropy and intracellular levels of cAMP, respectively. However, in hCG-treated cells 
with low numbers of LHR, there are increased cluster sizes and activity of LHR. In cells 
expressing high numbers of LHR per cell, receptors unable to under further aggregation 
upon binding hCG. In addition, we hypothesize that cells treated with an hCG antagonist 
DG-hCG or with MβCD have reduced cluster sizes and reduced activity at all expression 
levels of LHR. However, effects are more pronounced where cells express higher numbers of 






2.4. Project Rationale  
LHR are GPCR that are critical in the maturation of cells within the gonads and in 
reproductive function in both mammalian sexes [22]. Notwithstanding progress in studying LHR, 
we still do not know the effect of expression levels of hLHR on the size of clusters containing 
those receptors.  Also, we do not know if the expression level of LHR can play a role in changing 
the response of LHR to hormone agonists or antagonists and receptor activity.  Understanding 
these questions may provide new strategies for developing therapies to treat LHR-related diseases. 
As examples, Alzheimer’s disease [56-61], ovarian cancer [33, 62-64], breast cancer [65-68], 
prostate cancer [33, 69, 70], endometrial carcinomas [71-74], polycystic ovary syndrome [35, 40, 
75, 76], uterine leiomyoma [33, 77], adrenocortical dysfunction [36] obesity [39] and Cushing’s 
syndrome [78, 79] may be associated with over expression of LHR.  These diseases may in fact be 
caused by an increase in receptor cluster size and abnormal signal transduction leading to cell 
proliferation and protection from apoptosis, particularly in cancer cells.   
When developing cell lines used in these studies, it was also important to consider that 
the expression levels of LHR in the human ovary varies depending on the stage of follicular 
development or the age of the corpus luteum formed after ovulation.  Expression levels of LHR 
are positively correlated with oocyte maturation stage. However, when LHR were expressed in 
in high numbers, the fertilization rate was decreased [40, 250]. Thus, it is very important to 
consider threshold levels of LHR at each stage of the follicular phase or luteal phase of the 
ovarian cycle and to examine a range of receptor numbers that include naturally occurring 
numbers of LHR per cell (Table 1). This study also provides novel information about the role 
of expression levels of LHR on receptor clustering and function.  Such information will have 
utility in vitro fertilization (IVF) and in vitro maturation (IVM) protocols given the observation 
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that circulating LH levels in IVF patients affect implantation of the embryo [251].  There are 
also diagnostic implications of these results for patients with endometrial cancer.   In uveal 
melanoma cell lines, expression levels of LHR could be used for cancer diagnostic purposes 
since LHR play a role in growth and invasion of cancer cells.  The inactivation of LHR has the 























3.1. Introduction to methodological approach 
LHR are members of the superfamily of GPCR and are mainly present in gonadal cells 
such as Leydig cells and Sertoli cells in males and in theca, interstitial, cumulus and granulosa 
cells in the follicle and luteal cells in the corpus luteum in females. LHR in these structures are 
critical to the maturation and function of reproductive systems in both mammalian sexes [2, 28-
31, 85].  LHR are also found in a number of non-gonadal cells such as prostate [32], breast [33], 
human uterus [4, 28], brain [2, 57], human skin [34, 253] retina [253, 254], and adrenal cortex [33, 
35, 36] although the role of LHR in these tissues remains unclear.   
Recently it has become clear that many unstimulated GPCR including LHR exist in the 
plasma membrane as dimers or oligomers.  Dimerization or oligomerization of GPCR seems to 
occur early in receptor biosynthesis in the endoplasmic reticulum and, at this point in the receptor 
life cycle, is unrelated to receptor activation [2, 27, 192]. However, once inserted in the plasma 
membrane, ligand binding to the receptor can increase, decrease or no effect on oligomerization 
of GPCR depending on the type of receptor being examined.  For LHR, receptors appear to be 
inserted in the plasma membrane as dimers or small oligomers [2, 27, 192] and undergo further 
oligomerization after binding of hormone.  
LHR have been found to be clustered in dimers or oligomers in the plasma membrane using 
florescence resonance energy transfer methods such as homo-FRET and BRET [149, 192], FCCS 
[7], PD-PALM [140] and co- immunoprecipitation [193]. Activated LHR that have bound hLH or 
hCG appear to be clustered in the plasma membrane. This has been suggested in fluorescence 
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recovery after photobleaching studies [8, 194], experiments using FRET methods such as homo-
FRET and hetero-FRET [3, 8, 118, 149, 182], electron microscopy with ferritin-labeled LH [195], 
or co- immunoprecipitation  of tagged receptors [193]. There are some studies, however, using 
hetero-transfer FRET, that suggest that LHR stably expressed in Chinese hamster ovary (CHO) 
cells exist as monomers in the absence of hormone [182]. This may depend on low receptor 
expression levels that favor membrane expression of LHR as monomers instead of dimers or 
oligomers [2, 7, 27, 140, 149, 192, 193, 255].  
Several studies have found a number of human diseases related to LHR expression.  AD 
[56-61], ovarian cancer [33, 62-64], breast cancer [65-68], prostate cancer [33, 69, 70], 
endometrial carcinomas [71-74], polycystic ovary syndrome [35, 40, 75, 76], uterine leiomyoma 
[33, 77], adrenocortical dysfunction [36] obesity [39] and Cushing’s syndrome [78, 79] are 
associated with over-expression of LHR and high secretion of LH. Endometriosis is associated 
with low expression of LHR [33, 73].  
Increased expression of membrane proteins including LHR leads to molecular crowding in 
the membrane [158, 160]. Molecular crowding can affect molecule structure including folding, 
shape, conformational stability, molecule diffusion and molecular behavior including the ability 
to bind other molecules, enzymatic activity, and downstream signaling. Thus, molecular crowding 
affects protein and, more generally, cell function [119, 149, 158-160].  Changes in LHR expression 
levels might alter or affect oligomerization of the receptor as well as its function. This prediction 
derives from observations that overexpression of proteins leads to a crowded membrane 
environment and an increase in protein oligomerization [10]. Thus, oligomerization of LHR 
resulting from high expression levels may also contribute to these human diseases. It is therefore 
prudent to consider the potential influence of protein expression levels on the oligomerization state 
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of proteins, particularly for those proteins like LHR that are expressed in low numbers under 
physiologic conditions [46, 160]. 
Our initial studies (Figure 21) used homo-FRET techniques to show that 37,000 LHR per 
cell stably expressed in CHO cells were more likely to exist as dimers, a result in agreement with 
results obtained using other methods suggesting that LHR exist as constitutive dimers [2, 7, 27, 
140, 149, 192, 193, 255]. In addition, when cells were treated with 100 nM hGC, LHR appeared 
to form high order oligomers [196]. To investigate how the expression level of LHR impacts the 
receptor-containing clusters, we assessed the effect of LHR expression levels on the 
oligomerization states of unbound receptors and of receptors on cells treated with hCG or DG-
hCG. We also examined the effects of cholesterol depletion on receptor oligomerization and the 
receptor’s ability to signal productively. Four stable cell lines that differed in expression levels of 
LHR were generated. We measured changes in receptor cluster size in each cell line using homo-
FRET techniques and then explored the effect of LHR numbers and the receptor oligomerization 
state on intracellular cAMP levels using the ICUE3 probe.  
 
3.2. Methods and Materials  
3.2.1. Materials  
CHO-K1 cells were kindly provided by Dr. Takamitsu Kato in Department of 
Environmental and Radiological Health Sciences at Colorado State University. These cells 
were purchased originally from American Type Culture Collection (Manassas, VA). Dulbecco’s 
Modified Eagle medium (DMEM) and geneticin were purchased from Corning Cellgro (Visalia, 
CA). Penicillin/streptomycin (P/S) and L-glutamine solution were purchased from Gemini Bio-
Products (West Sacramento, CA). Fetal bovine serum (FBS) was purchased from Atlas Biologicals 
(Fort Collins, CO). 100 x MEM non-essential amino acid solution, bovine albumin and 
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ethylenediaminetetraacetic acid (EDTA) were purchased form Sigma-Aldrich (St. Louis, MO). 
Trypsin-EDTA (0.25%) was purchased form Fisher Scientific Co (Pittsburgh, PA). Rhodamine 
6G was purchased from Eastman Kodak (Rochester, New York). Lipofectamine 3000 was 
purchased from Life Technologies (Carlsbad, CA). Quantum FITC MESF (molecules of 
equivalent soluble fluorophore) beads were purchased from Bangs Laboratories, lnc. (Fishers, IN). 
Optimal-MEMTM was purchased form Life Technologies (Carlsbad, CA). hCG was purchased 
from Fitzgerald Industries (Acton, MA). DG-hCG was kindly provided by Dr. George R. 
Bousfield, Department of Biological Sciences at Wichita State University. WillCo glass bottom 
cell culture dishes with 35 mm diameter wells were purchased from In Vitro Scientific (Sunnyvale, 
CA).  A plasmid containing the entire coding region of the human LHR sub-cloned into pEYFP-
N1 was kindly prepared by Dr.Ying Lei (Figure 22). For western blots, the primary antibody used 
was a Chp grade anti-GFP antibody.  The secondary antibody was a HRP-conjugated anti-rabbit 
antibody that was kindly provided by Dr. Claudia Wiese in the Department of Environmental 
and Radiological Health Sciences at Colorado State University. For cAMP measurements, the 
ICUE3 plasmid was provided by Dr. Jin Zhang. Forskolin was purchased from Enzo Life Sciences 
(New York, NY).  MDL-12,330a hydrochloride was purchased form Sigma-Aldrich (St. Louis, 
MO). For lipid fluidity measurement, the phase-sensitive aminonaphthyl ethenylpyridinium-based 
dye, Di-4-ANEPPDHQ was purchased from Invitrogen (Carlsbad, CA). 
 
3.2.2. Cell lines 
  CHO cells stably expressing LHR were prepared with 0.5 μg/µL of hLHR-eYFP plasmid 
using Lipofectamine 3000 in accordance with Manufacturer’s instructions.  Contents of a 
microcentrifuge tube containing 125 μL of optimal-MEMTM Media and 7.5 μL Lipofectamine 
3000 reagent were mixed with contents of a second microcentrifuge tube containing 250 μL of 
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optimal-MEM medium, 2.5 μg/µL of hLHR-eYFP and 2 µL/µg DNA of Lipofectamine 3000 and 
incubated at room temperature for 10-15 minutes. The mixture was then added to cells in one well 
of a 6-well plate. Transfection of the cells progressed for 24 - 48 hours.  
 For stable cell line selection, optimal-MEM medium was replaced with medium containing 
G418 and cells were fed every 2-3 days with fresh medium. After 2-3 weeks post-transfection, 
cells were selected that stably incorporated the hLHR-eYFP plasmid into their genomic DNA. 
Negative and positive controls for transfection were included.  In one negative control, cells 
incubated without hLHR-eYFP or pEGFP plasmids and without G418 were expected to be alive 
in the end of selection process. In a second negative control, cells without hLHR- eYFP or pEGFP 
plasmid and with media containing G418, were expected to have died by the end the selection 
process.   
Stable cell lines were maintained in DMEM with 10% FBS, 1% P/S, 1% L-glutamine, 1% 
1x non-essential amino acids and 200 μg/mL of geneticin. Untransfected CHO cells were 
maintained in DMEM with 10% FBS, 1% P/S, 1% L-glutamine, 1% 1x non-essential amino acids 
but without 200 μg/mL of geneticin.  These two cell populations were maintained in 5% CO2 at 
37°C. 
 
3.2.3. Western immunoblotting for evaluation of plasma membrane expression of LHR 
Cells plated in 35 mm dishes were lysed in lysis buffer (pH 6.8) containing 150 mM NaCl, 
100 mM Tris-buffered saline (pH 8), 1% Tween 20, 50 mM diethyldithiocarbamate, 1 mM EDTA, 
and 1 mM phenylmethylsulfonyl fluoride. A protease inhibitor was added together with the lysis 
buffer. Cell were sonicated 5 times for 1 sec on ice. Then, supernatants of centrifuge lysates that 
had been centrifuged at 12,000 rpm at 4 °C for 30 min were transferred to new tubes. The protein 
concentration of each tube was determined using a BCA protein assay kit. Approximately, 50 µg 
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of protein containing hLHR and 5x sample buffer was incubated at 100 °C for 5 min. Samples 
were run on 10% SDS-polyacrylamide gels and transferred to polyvinylidene fluoride or 
polyvinylidene difluoride (PVDF) membranes. The membranes were blocked overnight in 5% 
non-fat dry milk in TBST and incubated for one hour at 4 °C with anti-GFP antibody diluted 
1:10000 in 5% non- fat dry milk in Tris-buffered saline with Tween (TBST).   Membranes were 
then washed with PBS two times for 5 min.  HRP-conjugated anti-rabbit antibodies were added 
for 60 min at room temperature followed by washing with PBS and detection using enhanced 
luminol-based chemiluminescent substrate kit as described by the Manufacturer. As a loading 
control, α-tubulin primary antibody was incubated for 60 min at a 1:1000 dilution in 5% non-fat 
dry milk in TBST followed by a 60 min incubation with HRP-conjugated anti-rabbit antibodies.   
 
3.2.4. Sample preparation for flow cytometry sorting  
Cells were grown to 80-90% confluence in a 25 cm2
 
culture flask and then incubated with 
1.0 ml trypsin-EDTA (0.25%) for 3 min. The flask was lightly washed with 3 mL of 1xPBS and 
the 3 mL effluent containing cells was placed into a 5 mL VWR polypropylene tube for flow 
cytometric analysis. Cells number needed to be between 105 and 106 cells per mL.  The Moflo 
Astrios EQ flow cytometer located in the Molecular and Radiation Biology Building at Colorado 
State University was used in these experiments. Fluorescence intensity was collected using a 488 
nm argon ion laser as an excitation source and a 525/40 nm emission filter.  Moflo Astrios EQ 
software was used to obtain fluorescence signal intensities from individual cells or from Quantum 
FITC molecules of equivalent soluble fluorophores (MESF) bead standards.  
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3.2.5. Flow cytometry data analysis 
To quantify LHR numbers expressed on stably transfected cells, Quantum FITC MESF 
bead standards were used. In a Quantum MESF kit, each microsphere population had a MESF 
value that was equivalent to the number of FITC molecules in solution.  The MESF values for the 
blank, bead standard 1, bead standard 2, bead standard 3, bead standard 4 and bead standard 5 were 
zero, 2003, 11639, 43155, 179437 and 527664 fluorescein equivalents, respectively. The intensity 
values for the bead standards in flow cytometry are shown in Figure 23.  The signals measured 
for hLHR-eYFP on the cell surface required that those signals be related to signals from the 
Quantum FITC-MESF beads. The beads needed to be analyzed for signal on the same day, in the 
same buffer used for hLHR-eYFP cell samples and using the same instrument settings such as 
amplifier gain, compensation and PMT voltage.   
Since there are no bead standards for eYFP, the measurements for FITC standard beads 
was converted to eYFP fluorophore signals obtained from cell samples using the following 
calculations.  The relative fluorescence signal RB for one bead molecule measured in the cytometer 
was obtained using the Equation 3  
                                                   (3) 
where εB (λmax,B) is the molar absorptivity coefficient of the given bead dye molecule. at its 
maximum absorption wavelength λmax,B, ΦB is fluorescence quantum yield, a(λexc,B) is the 
fractional absorbance for the bead dye molecule at the excitation wavelength λexc,B. a(λmax,B) is the 
fractional absorbance for the bead dye molecule at the maximum absorbance value. The upper 
integral in Eq. 3 is the integral of the bead fluorophore corrected emission intensity fB(λ) times the 
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is the corresponding integral over all wavelength spectra from 250 nm to 650 nm. The constant A, 
Equation 4 , essentially unimportant here, involves the exciting light wavelength λ, the intensity 
I on the chromophore of exciting light, the efficiency e of delivery of fluorescence photons to the 
detector and subsequent detection of primary photoelectrons, Avogadro’s number NA, Planck’s 
constant h and the speed of light c. 
                                                                                    (4) 
 The detected fluorescence signal RP for one fluorescent protein molecule (eYFP) on a cell 
is given by Equation 3 but with all subscript “B” changed to “P” to indicate quantities for the 
fluorescent protein instead of beads. The ratio RB / RP can thus be calculated for a pair of bead and 
protein fluorophores from photophysical data.  
 Cytometric measurements of beads using emission filters appropriate to the target protein 
provided calibration curves of the Manufacturer’s numbers NB of FITC per bead versus measured 
mean fluorescence intensity SB of FITC per bead. The slope NB//SB of such a curve is the number 
of bead fluorophores per unit bead fluorescence detected under conditions used to measure the 
protein of interest. Measurements of protein fluorescence SP were then obtained for cells using the 
same emission filters.  Finally, the number of fluorescent hLHR-eYFP molecules NP expressed on 
each cell is given by Equation 5   
                       (5) 
where SB is fluorescence signal for beads containing NB number of dye molecules and SP is the 
fluorescence signal of a particular cell. The ratio RB / RP  as described above. 
To calculate YFP numbers from measurements on FITC beads [256], we used the peak 
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absorptivity, 0.77 at an excitation wavelength of 488 nm, and the YFP fluorescence quantum yield 
of 0.48. The (upper) integral over the filter bandwidth is 778 nm, and the total emission (lower) 
integral is 5010 nm. Equation 3 then gives Rb as A*4373 s-1. In addition, it is known that YFP has 
a peak molar absorptivity of 84,000 L mol
-1 cm
-1 at 514 nm, that the fraction of that maximum 
molar absorptivity is 0.38 at an excitation wavelength of 488 nm, that the fluorescence quantum 
yield is 0.61. the (upper) integral over the filter bandwidth is 626 nm, and the total emission (lower) 
integral is 3808 nm. From Equation 3, RP is A*3212 s-1. Thus, the ratio RB /RP is 1.36, 
consequently, the number of YFP per cell is 1.36 times the number that would be inferred from 
FITC bead standards assuming the cells bore FITC-tagged molecules. Table 3 summarizes the 
numbers used in this calculation. 
 
3.2.6. Treatment of cells  
Stock solutions of 10	µM of hCG, 10	µM DG-hCG, 100 mM MβCD, 100μM forskolin, and 
10 μM of cis-N-(2-Phenylcyclopentyl)-azacyclotridec-1-en-2-amine hydrochloride (MDL-
12,330a hydrochloride) were made by dissolving these compounds in phosphate-buffered 
saline (PBS) containing 1mM CaCl2 and 0.5 mM MgCl2 and adjusting the pH to 7.4. 
For experimental measurements, the final concentrations of hCG and DG-hCG used 
experimentally were 100 nM, 30 nM, 10 nM, 1 nM and 0.1 nM.  10mM MβCD was used for 
cholesterol depletion. 50μM forskolin was used as cAMP positive control, and 10 μM MDL-
12,330a hydrochloride was used as cAMP negative control. 
 
3.2.7. Sample preparation for polarized homo-FRET experiments  
Four populations of stable cell lines expressing averages of 10,000, 32,000, 123,000 or 
560,000 LHR per cell were established.  Cells were grown to 80-90% confluence in 25 cm2 culture 
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flask and then incubated with 1.0 ml trypsin-EDTA (0.25%) for 3 min.  Cells (0.5 mL) were plated 
in a 35 mm glass bottom petri dish and, after 6-12 hours, were washed twice with 1xPBS (pH 7.3) 
and suspended with solutions of PBS alone or with MβCD  for 1hr or various concentrations of 
hCG, or DG-hCG for 1 hr. One hr was sufficient for hCG to activate LHR and for hormone effects 
on the formation of LHR clusters.  It has previously been shown that clustering of LHR receptors 
occurs within minutes and these clusters do not dissociate for several hours [8, 194]. After taking 
the dishes from the incubator, cells were washed once, resuspended in 1x PBS and immediately 
imaged with a Zeiss Axiovert 200M inverted microscope. For untreated cells, the cell pellet was 
resuspended in PBS alone.  
 
3.2.8. Homo-FRET measurements  
Energy transfer between chromophores such as eYFP molecules occurs only when donor 
eYFP and acceptor eYFP are within 2-10 nm of one another [257]. To measure homo-FRET, a 
Zeiss Axiovert 200M inverted microscope with an Andor DU897E EMCCD camera was used. 
Images were acquired using an arc lamp for fluorescence excitation together with a polarized 
excitation filter. Fluorescence emission was collected using eYFP emission filter and a 63x water 
objective for observing cells. All filters were from Chroma Technology. Figure 24 showed the 
experimental setup that used in this measurement.  Cells were photobleached for 15 minutes. One 
image was obtained each minute using a 15 second exposure time. Parallel and perpendicular 
fluorescence emission images were obtained simultaneously using a Photometrics Dual View 
image dissector.  These images were oriented with respect to the polarization of the exciting light.  
The microscope focus was adjusted so that the cell membrane appeared as a ring-like shape. 
Background was subtracted from fluorescence emission images. MetaMorph software allowed us 
to acquire and visualize cells during individual experiments.  
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Image J software was used for the calculation of the fluorescence anisotropy by obtaining 
the parallel and perpendicular fluorescence intensities from cell measurements and rejecting out 
fluorescence intensities from cell cytoplasmic.  These intensities were used to calculate anisotropy.  
The fundamental anisotropy (r0) of eYFP fluorophore is 0.38 [171, 230] and we assumed that the 
fundamental anisotropy of LHR tagged with eYFP was close to ~0.38 which represents an 
immobile monomer receptor. The intrinsic anisotropy was adjusted to 0.38. For each petri dish, 5-
7 cells were recorded for a total of at least 30 cells for each treatment. To avoid internalization of 
LHR, images were acquired within 30 minutes for each petri dish used [241].  
 
3.2.9. Experimental determination of the G factor  
The G factor was calculated using rhodamine 6G dye to correct for efficiency differences 
in instrument optics. The G factor in Equation 6 is the correction factor for differences in vertical 
and horizontal polarized fluorescence detection sensitivity in our instrumental setup. The G factor 
compensates for optical properties such as reflections from mirrors, objective or lenses that may 
change the polarization of excitation light. The G factor can be estimated from a reference aqueous 
solution with a known anisotropy value near zero such as rhodamine 6G. Rhodamine 6G has an 
anisotropy value of about 0.012 and emits completely depolarized light because it can rotate freely 
and quickly. During measurement of the G factor, the polarization excitation filter is removed and 
rhodamine 6G (R6G) is excited by a depolarized light source. Since the anisotropy of rhodamine 
6G is expected to be zero, The G factor can simply be calculated by the following equations  
                                              G= Iv/ Ih             (6) 
where Iv is the intensity of emission that is vertically oriented and Ih is the intensity of emission 
that is horizontally oriented with respect to the non-polarized excitation light. 
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A background was measured using water and under the same conditions used to examine 
R6G.  This background was subtraced from Rhodamine 6G signal before calculating the G factor 
using Image J.  In an ideal setup, G would be equal to one. However, in our instrument the G factor 
ranged from 1.27 to 1.34.  This means that the detection sensitivity in our instrument was higher 
for parallel polarization measurements than it was for perpendicular polarization measurements.  
The G factor was then used to calculate the fluorescence anisotropy r.  
 
3.2.10. ICUE3 transient transfection for measurement of intracellular cAMP 
The four stable cells lines with an average of 10K, 32K, 122K or 560K hLHR- eYFP per 
cell were transiently transfected with 0.4 μg of cAMP level reporter ICUE3 plasmid provided by 
Dr. Jin Zhang using Lipofectamine 3000 in accordance with the Manufacturer’s instructions. The 
contents of two sterilized microcentrifuge tubes, one containing 125 μL of optimal-MEMTM Media 
and 7.5 μL Lipofectamine 3000 and the other containing 250 μL of optimal-MEM Medium, 0.4 
μg of ICUE3 and 5 µL Lipofectamine 3000, were mixed and incubated at room temperature for 
10-15 minutes. This mixture was then added to the cells in a 35 mm petri dish containing 1mL 
optimal-MEMTM Media. Transfection took approximately 24-48 hrs.  Cells were maintained in 5% 
CO2 at 37°C during ICUE3 transfection.  
 
3.2.11. Sample preparation for hetero-FRET studies of intracellular cAMP using ICUE3  
Following transient transfection with ICUE3, cells were washed twice with 1xPBS, pH 7.3, 
and suspended in PBS, hCG, DG-hCG, 50nM forskolin or 100 μM MDL-12,330a hydrochloride. 
Forskolin was used as a positive control to activate adenylate cyclase. MDL-12,330a 
hydrochloride inhibits adenylate cyclase and serves as a negative control. After taking dishes from 
the incubator, cells were washed once, resuspended in PBS and immediately imaged. Seven 
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images of untreated cells were acquired every minute for 6 minutes beginning at time zero.  
Treatments were then added with 15 min incubation and then 10 images were acquired every 
minute. All images were acquired using a 63x 1.2 NA water objective and a Zeiss Axiovert 200M 
inverted microscope with an Andor DU897E EMCCD camera.  Images were acquired using an arc 
lamp with a 436DF20 excitation filter and two emission filters, 480DF40 for CFP and 535DF30 
for YFP and YFP sensitized emission (YFPSE) due to energy transfer from CFP. All filters were 
from Chroma Technology. Figure 25 shows the experimental set up that used in this measurement. 
MetaFluor software was used to observe and image cells during experiments. Images were 
acquired at 60s intervals. Backgrounds were subtracted from fluorescence images and data were 
analyzed using Image J software to calculate the emission intensity ratios CFP/YFPSE. For each 
petri dish, 2-5 cells were observed and data were collected from a total of  15 cells in various dishes 
for each treatment [256]. 
 
3.2.12. Measurement of plasma membrane lipid order  
Four stable cell lines (10K, 32K, 122K, and 560K LHR per cell) and untransfected CHO 
cells were grown to 80-90% confluence in 25 cm2 culture flasks and then incubated with 1.0 mL 
trypsin-EDTA (0.25%) for 3 min. Cells (0.5 mL) were seeded into a 35 mm glass-bottom petri 
dish. After 12 hours, cells were washed twice with 1x PBS (pH 7.3) and labeled and suspended in 
200 µL of 1.5 μM the environmentally-sensitive dye di-4-ANEPPDHQ for 15 min, washed and 
immersed in 1x PBS buffer for imaging using a Zeiss Axiovert 200M inverted microscope 
equipped with a 63x 1.2 NA water objective and an Andor Du897E EMCCD camera Cell samples 
were illuminated with an arc lamp with a 480/30x or 495/20x excitation filter. Fluorescence 
emission was collected simultaneously in channel 1 using a 535/40nm filter and in channel 2 using 
a 620/40 nm filter. MetaFluor software was used to observe and image cells during experiments. 
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Background correction for each image and fluorescence intensity ratio of 620nm/535nm 
calculation were performed using Image J. Images of control cells not labeled with di-4-
ANEPPDHQ were subtracted from the four population groups to remove fluorescence from eYFP-
LHR.  
 
3.2.13. Statistical analysis  
Data are expressed as the mean ± SEM. Statistical evaluation of mean differences between 
untreated groups and treatment groups were analyzed by one-way ANOVA followed by the Tukey 
multiple comparison test and Student's t-test to compare between two groups using R version 3.3.1. 








4.1. The effect of expression level on cluster size of LHR. 
Changes in expression level might alter and affect the oligomerization state and function 
of LHR since it has been found that the overexpression of proteins leads to a crowded environment 
and can increase the likelihood of protein oligomerization [10]. Our initial data using homo-FRET 
suggested that LHR might exist mainly as dimers, a result in agreement with results suggesting 
that LHR exist as constitutive dimers [2, 7, 27, 140, 149, 192, 193, 255]. However, other studies 
suggest that LHR exist as monomers in the absence of hormone [182]. The conflict may raise from 
the differences in expression level, high values of which might drive aggregation of LHR 
monomers into dimers or oligomers as seen by others [2, 7, 27, 140, 149, 192, 193, 255]. To 
investigate how the expression level of LHR impacts the cluster size of LHR, we assessed the 
effect of LHR numbers on the oligomerization state of unstimulated cells and cells treated with 
hCG, DG-hCG and MβCD. Thus, four cell lines that differ in expression levels of LHR were 
generated. We then measured the cluster size in each of them using homo-FRET techniques. The 
oligomerization of LHR that might result from high expression levels may also contribute to 
human diseases related to LHR aggregation. Therefore, the potential influence of expression level 
on oligomerization state of proteins specially those proteins that naturally exist at low expression 
level as do LHR [46, 160], must be considered. 
 
4.1.1. Characterization of cell lines stably expressing LHR 
Stable CHO cell lines expressing LHR-eYFP were generated as shown in Figure 26A.  
Images of membrane-associated fluorescence from LHR-eYFP were obtained with a Zeiss 
Axiovert 200M inverted microscope and expression was confirmed using western blot analysis as 
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shown in Figure 26 B. Lanes 2 and 3 in Figure 26 B2 are stable cell lines expressing LHR-eYFP 
with different loading concentrations.  
After confirming expression of functional LHR-eYFP, we used flow cytometry to sort four 
populations of these cells based on the number of LHR per cell as established using FITC bead 
standards (Figure 23).  Cell populations expressing an average of 10,000 LHR per cell, 32,000 
LHR per cell, 122,000LHR per cell or 560,000 LHR per cell were obtained. Calibration curve for 
conversion of the receptors number per cell in flow cytometry to numbers of receptor per cell in 
fluorescence is shown in Appendix I. 
 
4.1.2. Fluorescence anisotropy of LHR is dependent of receptor expression level 
 The oligomerization of membrane proteins such as LHR is often necessary for function.  
The oligomerization state of LHR in live cells was observed using polarized homo-FRET 
measurements and was manifest as a decrease in fluorescence anisotropy with increasing cluster 
sizes.  Experimentally, homo-FRET results were quantitated from an increase in fluorescence 
anisotropy upon fluorescence photobleaching, i.e., steady state anisotropy. The enhancement of 
florescence anisotropy upon photobleaching was used to distinguish between protein rotational 
effects and homo-FRET effects on anisotropy [171, 207, 208]. Photobleaching effectively reduced 
the number of fluorophores in a cluster over time.  This led to an increase in fluorescence 
anisotropy and reduced transfer of energy between eYFP molecules due to the reduced numbers 
of fluorescence acceptors.  Therefore, increases in anisotropy resulted from decreased energy 
transfer in response to fluorophore photobleaching.   
 A simulation of fluorescence anisotropy enhancement upon photobleaching is shown in 
Figure 27. This shows simulated anisotropy curves for photobleaching of homogeneous 
populations of monomers, dimers, and higher-order oligomers. Photobleaching of a homogeneous 
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population of monomers does not change the fluorescence anisotropy values while higher order 
oligomers demonstrate an upward, curved increase in anisotropy with photobleaching.   
 Examination of cell lines expressing LHR showed initial fluorescence anisotropy 
significantly lower than predicted for monomeric proteins, 0.38. This indicates that LHR are likely 
to exist as mixtures of monomers and dimers or some high aggregate, (Figure 28).  With increased 
expression of LHR as shown in Figure 29-31, it appears that receptors exist in a more crowded 
environments with increased numbers of dimers and larger oligomers.  This is a reasonable result 
based on previous observations that receptors such as neurokinin-1 receptors, when over-expressed 
in cells, are more extensively clustered than when the same receptors are expressed in lower 
numbers in the same cell type [10]. In contrast, the oligomerization state of serotonin1A receptors 
in cells is independent of expression levels [171] as has also been reported for GPI-anchored 
proteins [161]. This suggests that there is no single model for the relationship between protein 
oligomerization and protein expression levels. Thus, it is very important to study the relationship 
between oligomerization and expression levels for each protein on an individual basis. 
 Figures 29 examines in more detail the relationship between initial fluorescence anisotropy 
and LHR expression levels.  These results suggest that the oligomerization state of LHR is highly 
dependent on the number of LHR expressed per cell.  With increased expression, LHR become 
more clustered and fluorescence anisotropy decreases. These data are summarized in Table 4.      
The curvature found in Figure 29 for initial anisotropy for the four expression groups and 
Figure 30 for anisotropy during photobleaching for the four expression groups indicate that the 
cluster size of LHR is increased as LHR expression increased. Moreover, the correlation between 
anisotropy and receptors number per μm2 during photobleaching is shown in Appendix I. 
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4.1.3. Effects of hCG on LHR oligomerization  
GPCR can function as monomers, dimers or oligomers after binding ligand. Such ligation 
can either increase, decrease or have no effect on the GPCR oligomerization state depending on 
receptor type [25].  Therefore, there are no general rules governing the effect of ligand binding on 
the degree of receptor oligomerization.   
LHR, upon binding hormone, exist as dimers or oligomers at the plasma membrane as 
suggested by fluorescence recovery after photobleaching studies [8, 194], use of fluorescence 
resonance energy transfer techniques such as homo-FRET or hetero-FRET [3, 8, 118, 149, 182], 
electron microscopic analysis of LHR using ferritin-labeled LH [195] and co-immunoprecipitation 
studies [193]. Moreover, we have found that the cluster size of hLHR increases in a hormone 
concentration-dependent manner [196]. Nevertheless, the effect of hCG on LHR oligomerization 
has not been studied using cells with well-defined numbers of receptors per cell.   
As shown in Figure 32, fluorescence anisotropy during photobleaching, serving as a 
readout for LHR oligomerization state was dependent on receptor expression levels. Treating cells 
that expressed low numbers of LHR per cell with 100 nM hCG produced a significant decrease 
(0.101±0.005) in anisotropy indicating that hormone binding increased LHR cluster size. When 
cells expressed higher numbers of LHR per cell and were treated with 100 nM hCG, there is no 
change in fluorescence anisotropy indicating that LHR are already aggregated and hormone 
binding does not drive further protein-protein interactions.   
Values for initial fluorescence anisotropies in hCG-treated cells as a function of LHR 
expression are shown in Table 5.  The effect of hCG on the cluster size of LHR was concentration-
dependent when cells expressed low numbers of LHR per cell (Figure 33). As the number of LHR 
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per cell increased, the effect of hormone on oligomerization of LHR was negligible, presumably 
because these receptors are aggregated already (Figure 33). 
 
4.1.4. Effect of DG-hCG on LHR oligomerization  
DG-hCG has been found in serum from male patients with chronic renal failure and 
suffering with hypogonadism [114].  The DG-hCG used in these studies was prepared using TFMS 
to remove carbohydrate groups [124, 125]. Chemically-modified DG-hCG binds LHR with the 
same affinity as hCG but exhibits little or no ability to stimulate cAMP levels within cells [112, 
114, 122, 123, 127-129]. Because DG-hCG also competes with hCG for binding to LHR DG-hCG 
is described as an hCG antagonist.    
The effect of DG-hCG on the oligomerization of LHR has not been extensively 
characterized, particular in cells where the number of LHR per cell is well characterized.  In 
experiments described here, concentration-dependent effects of DG-hCG on LHR oligomerization 
were evaluated as shown in Figure 34.  DG-hCG treatment increased fluorescence anisotropy in 
cells expressing an average of 10K LHR per cell indicating that it is likely that cluster size is 
reduced in response to DG-hCG.  Effects of DG-hCG were more pronounced with increases in the 
expression level of LHR per cell. The values for initial fluorescence anisotropies of DG-hCG-
treated cells with different concentration are shown in Table 6. 
 
4.1.5. Effect of cholesterol depletion on receptor oligomerization 
Membrane cholesterol has important roles in the function and organization of many 
membrane proteins [1, 166-173] and can modulate the stability of membrane protein dimers [173, 
179, 189, 190].  Depletion of cholesterol by MβCD affects the function of many proteins [1, 166-
168] although mechanistic details are not known.  Membrane cholesterol may interact directly or 
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indirectly with membrane proteins to induce conformational changes in proteins or alter the 
physical properties of lipid membranes.  Both of these cholesterol effects could, in turn, modulate 
formation of protein oligomers or alter the stability of protein oligomers [1, 164, 172, 177, 178]. 
Previous studies have suggested that membrane cholesterol is important in the formation of GPI-
anchored protein clusters [189], µ-opioid receptor clusters [190] and serotonin 1A receptor clusters 
[166, 171, 173, 188, 258].   
In this study we found that membrane cholesterol depletion affects LHR clusters in cells 
expressing both high and low receptor numbers. Thus, LHR clusters in the plasma membrane are 
associated with cholesterol-containing membrane microdomains and this association is 
independent of receptor expression levels (Figure 35). However, depletion of membrane 
cholesterol by MβCD had greater affects in cluster sizes in cell lines expressing higher numbers 
of LHR per cell (Figure 35). Given the number of GPCR and other membrane proteins that utilize 
cholesterol-enriched microdomains in signaling mechanisms, membrane microdomains may 
provide a drug target for reducing the effects of receptor over-expression in some disease processes 
by effectively increasing receptor monomers and limiting formation of dimers or higher order 
oligomers [259].   
hCG treatment of cells pre-treated with MβCD reduced the effect of MβCD on cluster size. 
This suggested that presence of hCG, after cells were treated with MβCD, might recruit cholesterol 
into association with LHR leading to a decreased effect of MβCD (Figure 35). The actual 
mechanism involved in hCG effects on cells pre-treated with MβCD remains unknown and its 
elucidation will require additional work. 
Other investigators have found that hCG effects on the production of endogenous 
testosterone could restore normal reproductive function in cells exposed to vanadium compounds 
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[260]. This observation agrees with our results from experiments where hCG treatment of cells 
pretreated with MβCD where hCG reduced effects of vanadium compounds. Interestingly, 
vanadium compounds were found to decrease cell-surface plasma membrane lipid order as 
assessed using di-4-ANEPPDHQ [261] in a manner similar to MβCD (Figure 36 ). Di-4-
ANEPPDHQ has been reported to be a useful tool for probing membrane lipid order in live cells.  
[261-264]. In cells treated with di-4-ANEPPDHQ, the spectral properties of the dye are altered in 
response to lipid packing. 
 
4.1.6. Effect of receptor oligomerization on cell plasma membrane lipid order  
Previous work has shown that the oligomerization state of LHR is dependent on the number 
of LHR expressed per cell.  When cells express higher numbers of LHR, receptors become 
clustered. This may be due to cholesterol stabilizing membrane protein dimers [173, 179, 189, 
190].  However, we found that cholesterol depletion affects LHR clusters. Thus, how the number 
of LHR per cell is related to LHR interactions in the plasma membrane was investigated by 
examining the changes in membrane lipid order using di-4ANEPPDHQ as previously described 
[261-263]. As shown in Figure 37, cells expressing 122K and 560K LHR per cell have 
640nm/545nm fluorescence emission ratios of 2.22±0.03 and 2.23±0.02, values that are 
significantly less than from ratios measured in cell lines expressing 10K or  32K LHR per cell. 
This indicates that tighter lipid packing occurs in cells expressing high number of LHR per cell 
and also explains why depletion of membrane cholesterol has greater effects on the 
oligomerization state of LHR in cells expressing 122K and 560K LHR per cell (Figure 35). This 
result also suggests that increased numbers of LHR per cell can lead to greater receptor association 
with cholesterol and that oligomers become more stable. Depletion of cholesterol in these cells 
may lead to a decrease in the cluster size (Figure 35). Thus, the role of cholesterol in forming and 
 80 
stabilizing the oligomerization of membrane proteins may be a promising area of research. 
Modulating that the concentration of cholesterol in the plasma membrane and, as a result, the 
oligomerization state of membrane proteins, might prove to be a helpful pharmacologic strategy 
[259]  
 
4.2. The effect of LHR expression levels as well as cluster size of LHR on receptor activity 
Molecular crowding resulting from high protein expression levels has effects on cell 
membrane molecular structure. These effects include change in folding, shape, conformational 
stability, diffusion, ligand binding, enzymatic activity, and downstream signaling [119, 149, 158-
160]. It also appears that the clustering of LHR plays an important role in signaling, desensitization 
and internalization of the receptors after activation by hormone [2-8]. Thus, the effect of the 
oligomerization state on receptor function is important.  
The overexpression of neurokinin-1 receptors leads to a crowded membrane environment 
and increases the receptor’s oligomerization state [138]. This may lead to increased intracellular 
cAMP. Also, it has been reported that the basal level of cAMP rises as the expression level of %2-
adrenergic receptors increases [265]. Based on our finding that increased expression levels of LHR 
lead to aggregation of LHR, the relationship between the expression level of LHR, cluster size and 
intracellular cAMP were assessed experimentally. 
To investigate how the expression level of LHR and cluster size of LHR are related, we 
evaluated the effects of LHR number and receptor oligomerization state on intracellular cAMP 
levels in unstimulated cells and cells stimulated with hCG, DG-hCG and MβCD. The ICUE3  
cAMP sensor was used to measure changes in intracellular cAMP in four population of cells with 
different expression levels of LHR. 
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4.2.1. High expression levels of LHR are associated with elevated intracellular   
 cAMP  
Previous studies have shown that a change in the expression level of wild type LHR from 
600 to 125,000 LHR/cell increases cAMP production in response to hormone as illustrated in 
Figure 14 [159]. In addition, studies using FSHR demonstrated that low expression levels of 
FSHR mimic the activity of a mutated FSHR (A189V) that is unable to produce cAMP even in 
present of hormone (Figure 13; [150]). However, there have been no studies evaluating the effect 
of LHR expression levels on production of cAMP when receptor numbers are well characterized.  
 In this project, the impact of expression levels of LHR on intracellular cAMP was evaluated using 
ICUE3 (Figure 20). This cAMP sensor has an N-terminally truncated Epac1 protein fused to an 
eCFP donor and a cpV-L194 (Venus) acceptor. Venus is an improved version of eYFP [231, 236, 
243] and is referred to as eYFP in this dissertation. In the absence of cAMP, ICUE3 folds in such 
a way that the distance between eCFP and eYFP is less than 10 nm.  When eCFP is excited with 
440 nm light, energy transfer from eCFP to eYFP occurs due the close proximity of these 
molecules so that donor emission overlaps with acceptor excitation wavelengths. As a result, there 
is a low level of eCFP emission. In the presence of cAMP, cAMP binds to ICUE3 which undergoes 
a conformation change causing separation of eCFP and EYFP. This is accompanied by reduced 
FRET.  Thus, an increase in the emission intensity ratio of eCFP to eYFP reflects cAMP presence. 
This permits monitoring relative changes in intracellular cAMP levels in response of LHR activity.   
As discussed above, the cluster size of LHR is dependent of receptor expression levels. 
Therefore, it is important to examine the effect of receptor expression on intracellular cAMP levels 
in unstimulated cells. Therefore, we evaluated the basal levels of intracellular cAMP in four cell 
populations with different LHR expression levels.  The data illustrated in Figure 38 indicate that 
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there is a positive relationship between LHR numbers per cell and receptor activity. This positive 
relationship was also found between LHR numbers per cell and receptor oligomerization (Figure 
31).  
 
4.2.2. hCG promotes an increase in intracellular cAMP when receptor numbers   
 per cell are low 
hCG was used to evaluate effects of hormone binding on intracellular cAMP as a function 
of LHR number. hCG treatment increased production of cAMP in cells that expressed 
comparatively fewer LHR per cell (Figure 39). However, cells with highly expressed LHR (32k 
and 560k  LHR per cell) had no significant change in cAMP levels suggesting that these LHR were 
maximally active even in the absence of hormone.   
 
4.2.3. DG-hCG alters LHR aggregation and reduces cAMP production 
Carbohydrate residues on hCG are essential for hormone function as well as for slowing 
of hCG clearance from the body [111-113]. When carbohydrates in hCG are removed by TFMS, 
DG-hCG results [124, 125].  DG-hCG binds LHR with the same affinity as hCG (Figure 9A) but 
results in little or no activation of AC to increase cAMP (Figure 9B; [112, 114, 122, 123, 127-
129]). Effects of DG-hCG are concentration-dependent [127] and, when the hormone is present in 
excess, can reduce the production of cAMP in cells treated with hCG or hLH [128, 132, 133].  This 
suggests that DG-hCG competes with these hormones for binding sites on LHR.  
In this study, the effect of LHR expression level on the impact of DG-hCG on intracellular 
cAMP was explored. The ICUE3 sensor was used to measure changes in intracellular cAMP in 
four population of cells with different expression levels of LHR. Results showed that DG-hCG 
effects were dependent on LHR expression level. As shown in Figure 40 and Table 6, the largest 
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effects of DG-hCG occurred when cells stably expressed higher numbers of LHR. At the lowest 
expression level of LHR, 10k LHR per cell, these was only a modest difference in cAMP levels 
between untreated cells having low basal levels of intracellular cAMP and cells treated with 100 
nM DG-hCG. Cell lines expressing either 122k LHR per cell or 560k LHR per cell exhibited 
reduced intracellular cAMP levels with DG-hCG treatment more than lowest expression level of 
LHR. Both of these cell lines have high basal levels of intracellular cAMP in the absence of 
hormone and their LHR are constitutively active.    
 
4.2.4. Effect of cholesterol depletion on cAMP production 
Membrane cholesterol plays an important role in the function and dynamics of many 
membrane proteins [1, 166-173]. In particular, it modulates formation of membrane protein dimers 
[173, 179, 189, 190]. Previous studies found that both functional LHR exposed to hCG and 
constitutively active LHR are present in membrane microdomains enriched with cholesterol while 
unliganded LHR are located in the bulk membrane [181, 182]. Thus, membrane cholesterol affects 
the activity of LHR which require intact, cholesterol-containing microdomains for function.  
Depletion of plasma membrane cholesterol using MβCD reduces the ability of LHR to signal in 
response to hormone binding and lowers intracellular cAMP [181]. As shown in Figure 40, MβCD 
reduces the level of intracellular cAMP as the expression level of LHR increased. MβCD treatment 
also reduces the size of receptor clusters, particularly when LHR are expressed at higher numbers 
of receptors per cell. Nonetheless, it is not clear precisely how cholesterol affects LHR function.  
Cholesterol may interact directly or indirectly with membrane proteins, e.g. LHR.  Direct 
interactions could alter the structure and function of the membrane protein in question while 
indirect effects on physical properties of membrane lipids could alter protein-protein interactions 
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and improve the stability of protein oligomers [1, 164, 172, 177, 178]. Measurements of cAMP 








Figure 21: Fluorescence anisotropy as function of time during fluorescence photobleaching for 







Figure 22: hLHR gene-containing plasmid used to generate stable hLHR-eYFP expressing cell 







Figure 23: Flow cytometry data.  The panel on the left shows the intensity histogram of the four 
Quantum FITC bead standards showing the number of beads (y-axis) detected in various 
fluorescence intensity channels (x-axis). The panel on the right is the calibration curve for the 
Quantum FITC bead standards relating Manufacturer’s numbers of fluorescein (FITC) molecules 







Figure 24: Schematic representation of the experimental setup used for homo-FRET 
measurements. The excitation filter and the parallel polarized detector are polarized vertically 
while the perpendicular polarized detector is polarized horizontally in the plane of the optical table. 
Sample images from the parallel- and perpendicular-polarized detectors are actually recorded side-








Figure 25: Schematic representation of the experimental setup used for hetero-FRET 
measurements.  This instrumental setup was used in ICUE3 experiments measuring intracellular 


















Figure 26: Experiments to confirm transfection of CHO cells with the hLHR-eYFP plasmid. The 
panel on the left shows CHO cells expressing hLHR-eYFP.  These images were acquired using a 
Zeiss Axiovert 200M inverted fluorescence microscope and show excellent membrane localization 
of the transfected receptor.  Panels on the right show western blots of molecular weight markers 
beside a blot showing a 105.6 kDa band that is hLHR-eYFP (blue arrows).  The western blot on 

















Figure 27: Simulated data for fluorescence anisotropy upon photobleaching. This graph indicates 
differences in initial anisotropy values and anisotropy values upon photobleaching for receptor 






























































Figure 28: Fluorescence anisotropy upon fluorescence photobleaching for 15 minutes for CHO 
cells with 10k hLHR per cell. The difference between the predicted anisotropy values for receptor 
monomers and extrapolated anisotropy in cells with less than 10k LHR per cell provides 
information on the cluster size of LHR. Data are presented as means ± SEM for n = 30 
measurements. The two lines are significantly different in one-way ANOVAs and Tukey’s 


























Figure 29: Correlation between initial anisotropy and initial fluorescence intensity for untreated 
cells. Symbols indicate average data for cells representing the four expression groups. This figure 
indicates that the oligomerization state of LHR is highly dependent on the expression level of LHR 
per cell. Data are presented in each point as the mean ± SEM for n = 10 measurements; the four 
cell lines were significantly different in one-way ANOVA and Tukey’s multiple comparisons tests 



































Figure 30: Correlation between anisotropy value and fluorescence intensities during 
photobleaching for untreated cells. Symbols indicate average data for cells representing the four 
expression groups.  The oligomerization state of LHR is highly dependent on the expression level 
of LHR per cell and has curvature as above. Data are presented in each point as the mean ± SEM 
for n = 10 measurements; the four cell lines were significantly different in one-way ANOVA and 
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Figure 31: Fluorescence anisotropy during photobleaching for 15 minutes in cells that express 
hLHR at different levels. The difference between the known values for monomer anisotropy and 
extrapolated anisotropies for LHR expressed in CHO cells provides information on the cluster size 
of LHR.  Data are presented as the means ± SEM for n = 30 measurements. Anisotropy values for 
the four cell lines were significantly different as analyzed by one-way ANOVA and Tukey’s 




























Figure 32: Correlation between anisotropy values and fluorescence intensities during 
photobleaching in cells treated with 100nM hCG. Symbols indicate average data for cells 
representing the four expression groups.  The figure indicates that the oligomerization state of 
LHR is highly dependent on the number of LHR per cell.   Data are presented in each point as the 
mean ± SEM.  Cells expressing 10k, 32k or either 122k and 560k LHR per cell were significantly 
different as analyzed by one-way ANOVA and Tukey’s multiple comparisons tests (p < 0.05). 
There are no significant differences between anisotropy values for cells expressing 122k or 560k 




























Figure 33: Average initial fluorescence anisotropy values for four cell lines in response to different 
hCG concentrations. The four cell lines differed in their expression levels of LHR. These results 
indicate that the effect of hCG on cluster size of LHR is concentration-dependent for cells 
expressing low numbers of LHR/cell. However, hCG treatment did not affect the LHR cluster size 
when cells expressed the higher value of 560k LHR per cell.  Data are presented as the mean ± 































Figure 34: Average initial fluorescence anisotropy for four cell lines in response to different DG-
hCG concentrations.  These results indicate that DG-hCG reduces the cluster size of LHR in a 
concentration-dependent manner, but effects are more apparent when the expression level of LHR 
is high. Data are presented in each bar as the mean ± SEM for n = 30 measurements; the four 
groups were significantly different as analyzed by one-way ANOVA and Tukey’s multiple 
































Figure 35: Average initial fluorescence anisotropy values for cells expressing various numbers of 
LHR per cell after treatment with MβCD.  After cholesterol depletion from cell membranes using 
MβCD, initial anisotropies increased in otherwise untreated cells and, to a lesser extent, hCG-
treated cells.  Data are presented in each bar as the mean ± SEM for n = 30 measurements.  There 
were no significant differences between effects of MβCD on cells expressing either 10k LHR per 
cell or 32k LHR per cell and cells expressing 122k LHR per cell or 560k LHR per cell.  There 
were significant differences between these two groups in response to MβCD analyzed by one-way 




























10 mM MβCD 
100 mM MβCD + 100 nMhCG
 100 
Table 3: Summary of fluorescence parameters for FITC and eYFP excited at 488 nm.  These 
quantities were used to convert the flow cytometer signal from FITC bead standards to numbers 



















FITC 77.3 100 68,000 2981 5010 0.95 28815 
eYFP 38.1 100 84,000 2723 3809 0.61 13956 
 
a relative chromophore absorbance at excitation wavelength  
b relative chromophore absorbance at peak absorption wavelength 
c chromophore peak molar absorptivity 
d total chromophore fluorescence within detector filter bandwidths 
e total chromophore fluorescence over all wavelengths 
f chromophore fluorescence quantum yield  
g relative measured fluorescence in arbitrary units for one chromophore of the indicated type  
 
a b e c d f g 
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Table 4: Summary of changes in fluorescence anisotropy upon fluorescence photobleaching for 
15 minutes in unstimulated cells expressing different average numbers of hLHR-eYFP per cell.   
 
 Mean of Anisotropy ±SEM 
        #LHR/Cell 
                 (average) 
time 
10k 32k 122k 560k 
0 0.20±0.01     0.13±0.002    0.08±0.003     0.05±0.003      
1 0.21±0.01 0.14±0.003 0.09±0.003 0.06±0.003 
2 0.21±0.02 0.14±0.003 0.09±0.004 0.06±0.01 
3 0.21±0.01 0.14±0.003 0.09±0.004 0.07±0.01 
4 0.22±0.01 0.14±0.01 0.10±0.01 0.07±0.01 
5 0.23±0.01 0.14±0.01 0.10±0.01 0.07±0.01 
6 0.23±0.01 0.15±0.01 0.10±0.01 0.07±0.01 
7 0.23±0.01 0.15±0.01 0.10±0.01 0.07±0.01 
8 0.24±0.01 0.15±0.01 0.10±0.01 0.07±0.01 
9 0.25±0.02 0.15±0.01 0.10±0.01 0.07±0.01 
10 0.24±0.02 0.15±0.01 0.10±0.01 0.08±0.01 
11 0.26±0.02 0.16±0.01 0.11±0.01 0.08±0.01 
12 0.27±0.02 0.17±0.01 0.11±0.01 0.08±0.01 
13 0.27±0.02 0.163±0.01 0.12±0.01 0.08±0.01 
14 0.28±0.02 0.17±0.01 0.12±0.01 0.08±0.01 
15 0.29±0.02 0.17±0.01 0.12±0.01 0.08±0.01 
 
Data are presented as means ± SEM for n=30 measurements. The four cell lines were significantly 
different as analyzed by one-way ANOVA and Tukey’s multiple comparisons test (p < 0.05).  
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Table 5: Summary of change in initial anisotropy in cell lines expressing hLHR and variously 
treated with hCG and or MβCD.  
 
 Mean of Initial Anisotropy ±SEM 
                    #LHR/Cell 
                           (average) 
treatment 
10K 32K 122K 560K 
Control 0.20±0.01a 0.13±0.002e 0.08±0.003f 0.05±0.003gh 
100 nM hCG 0.10±0.01b 0.08±0.003f 0.06±0.003gf 0.05±0.002h 
30nM hCG 0.11±0.01b 0.09±0.004bf 0.06±0.003gf 0.05±0.004h 
10nM hCG 0.17±0.01c 0.11±0.004b 0.09±0.003f 0.06±0.002gh 
1nM hCG 0.18±0.01c 0.11±0.004b 0.09±0.005f 0.06±0.003gh 
0.1nM hCG 0.18±0.01c 0.13±0.005e 0.09±0.002bf 0.06±0.002gh 
10 mM MβCD 0.22±0.01ad 0.20±0.004a 0.19±0.004ac 0.18±0.003ac 
10 mM MβCD +10nM hCG 0.22±0.01ad 0.20±0.003a 0.20±0.003 ac 0.17±0.03c 
 
Data are presented as means ± SEM for n = 30 measurements. Values with different superscripts 
were significantly different as analyzed by one-way ANOVA and Tukey’s multiple comparisons 




















Table 6: Summary of change in initial anisotropy in cell lines expressing hLHR and treated with 
various DG-hCG concentrations.   
 
 Mean of Initial Anisotropy ±SEM 
        #LHR/Cell 
                 (average) 
treatment 
10k 32k 122k 560k 
Control 0.20±0.01a 0.13±0.002c 0.08±0.003e 0.05±0.003g 
100 nM DG-hCG 0.23±0.01b 0.20±0.01a 0.14±0.003c 0.14±0.003c 
30 nM DG-hCG 0.22±0.01ab 0.18±0.01d 0.14±0.004c 0.12±0.004cf 
10 nM DG-hCG 0.21±0.01ab 0.13±0.004c 0.12±0.002cf 0.11±0.003f 
1 nM DG-hCG 0.21±0.01ab 0.13±0.004c 0.11±0.003f 0.08±0.002ef 
0.1 nM DG-hCG 0.20±0.01ab 0.13±0.003c 0.09±0.01ef 0.06±0.004efg 
 
Data are presented as means ± SEM for n = 30 measurements. Values with different superscripts 
were significantly different as analyzed by one-way ANOVA and Tukey’s multiple comparisons 







Figure 36: Fluorescence emission of Di-4-ANEPPDHQ labeled CHO cell membranes. Di-4-
ANEPPDHQ fluorescence emission was measured simultaneously at 545 nm and 640 nm.  The 
ratio of intensities at 640 nm to that at 545 nm was calculated as “Emission ratio”. Control CHO 
have no effect on Di-4- ANEPPDHQ emission.  There was, however, a significant increase in the 
emission ratio to a value of approximately 5 in cells treated with M678 and this indicates a 
significant decrease in membrane order caused by M678 treatment. Data are presented in each 
bar as the mean ± SEM for n=40 measurements and analyzed by one-way ANOVA and Tukey’s 



































Figure 37: Fluorescence emission of Di-4-ANEPPDHQ labeled the four groups of cells expressing 
various average numbers of LHR per cell. Di-4-ANEPPDHQ fluorescence emission was measured 
simultaneously at 545 nm and 640 nm and the ratio of intensities at 640 nm to that at 545 nm 
calculated as “Emission ratio”. Cells expressing 10k or 32k LHR per cell had significant increases 
in the emission ratio compared to cells with 122k or 560k LHR per cell. Data are presented in each 
bar as the mean ± SEM for n = 40 measurements and analyzed by one-way ANOVA and Tukey’s 
































Figure 38: Relationship between numbers of LHR per cell and ICUE3 sensor reading reflecting 
levels of cAMP per cell in untreated cells. The ICUE3 sensor emits both CFP fluor emssion at 480 
nm and YFP sensitized fluor emsission at 535 nm. Upon 435 nm excitation the ratio of CFP 
emission to YFP sensitized emission increases with cAMP concentration. Data are presented as 
the mean ± SEM for n = 15 measurements. cAMP levels were significantly different between the 













































Figure 39: Effect of hCG on intracellular cAMP concentration in variously treated cells. The 
ICUE3 sensor emits both CFP fluor emssion at 480 nm and YFP sensitized fluor emsission at 535 
nm.  Upon 435 nm excitation the ratio of CFP emission to YFP sensitized emission increases with 
cAMP concentration. Data are presented as the mean ± SEM for n = 15 measurements and were 

















































Figure 40: Effect of DG-hCG on production of cAMP in variously treated cells expressing 
different numbers of LHR per cell. The ICUE3 sensor emits both CFP fluor emssion at 480 nm 
and YFP sensitized fluor emsission at 535 nm. Upon 435 nm excitation the ratio of CFP emission 
to YFP sensitized emission increases with cAMP concentration. Forskolin was used as a positive 
control and MDL was used as a negative control. Data are presented in each bar as the mean ± 
SEM for n = 15 measurements and were analyzed by one-way ANOVA and Tukey’s multiple 
















































Figure 41: Effect of cholesterol depletion on production of cAMP in variously treated cells 
expressing different numbers of LHR per cell. The ICUE3 sensor emits both CFP fluor emssion at 
480 nm and YFP sensitized fluor emsission at 535 nm. Upon 435 nm excitation the ratio of CFP 
emission to YFP sensitized emission increases with cAMP concentration. Data are presented in 
each bar as the mean ± SEM for n = 15 measurements and analyzed by one-way ANOVA and 
Tukey’s multiple comparison’s test (p < 0.05). Forskolin was used as a positive control and MDL-













































Table 7: Summary of changes in intracellular cAMP as measured experimentally by changes in 
the CFP/YFPSE ratio.  Measurements were made on cells expressing hLHR at different levels and 
treated with hCG, DG-hCG, MbCD or forskolin.    
 
 Mean of CFP/YFPSE emission ratio at 435 nm ±SEM 
        #LHR/Cell 
                (average) 
treatment 
10K 32K 122K 560K 
Control 0.52±0.02 a 0.65±0.03e 0.73±0.02c 0.83±0.02 c 
100 nM hCG 1.01±0.01b 1.01±0.01b 0.79±0.001c 0.93±0.003c 
100 nM DG-hCG 0.47±0.003d 0.55±0.01ad 0.42±0.01df 0.31±0.01f 
10 mM MβCD 0.51±0.03ad 0.53±0.02ad 0.53±0.01ad 0.42±0.003df 
Forskolin 0.86±0.002c 1.06±0.01b 0.60±0.01ae 0.79±0.01 c 
MDL-12,330a 
hydrochloride 0.50±0.004 ad 0.53±0.01ad 0.53±0.003ad 0.59±0.01ae 
 
Data are presented as means ± SEM for n = 15 measurements. Differences between expression 
and treatment group were analyzed by one-way ANOVA and Tukey’s multiple comparison’s test. 
















Development of the reproductive organs and healthy function of the reproductive system 
in humans is impossible without normal function of LHR. Stimulation of sperm maturation and 
production of testosterone in males is regulated by LHR as is embryonic development of Leydig 
cells needed for testosterone secretion. In females, follicular development, ovulation, estrogen 
secretion and function of the corpus luteum require functional LHR.  During the first trimester of 
pregnancy, LHR are involved in maintaining progesterone secretion which, in turn, maintains the 
uterine lining. A better understanding of LHR function is invaluable to treating pathologic 
conditions related to LHR expression and function.   
 The expression level of LHR depends on a number of factors depending on the organ being 
studied.  What is clear, however, is that overexpression of membrane proteins like LHR results in 
a higher density of proteins, i.e. molecular crowding, which can affect receptor signaling, 
desensitization and internalization [2-8]. High molecular densities may also lead to 
oligomerization of the proteins [10].  
 There are disagreements in the literature with respect to the oligomerization state of 
inactive LHR [149, 182]. These disagreements may arise from differences in expression levels of 
LHR. In this study, we assessed the role of LHR expression on initial fluorescence anisotropy of 
receptors using homo-FRET methods and measurements of LHR activity. Receptor fluorescence 
anisotropy is decreased by receptor aggregation and so provides an indispensable means of 
assessing receptor aggregation on intact cells. The goal of this project was to establish how 
expression levels for a well-characterized GPCR affect receptor function.  Conclusions from these 
studies are illustrated in Figures 41-44.   
 112 
These studies suggest a possible mechanism involved in receptor-receptor interactions.  
Receptors interact with one another under various well-defined conditions.  For LHR that have not 
bound hCG, receptor cell surface density is a factor in receptor interactions. With increased surface 
density, i.e. higher expression, initial anisotropy values are lower, indicating that receptors are 
more extensively clustered.  The effects of hCG depend on the extent of “pre-clustering” of the 
receptor prior to hormone treatment. When receptor expression levels are lower, hCG binding to 
the receptor recruits additional receptors to existing as pre-clusters. This produces a further 
decrease in initial anisotropies, receptors become more extensively clustered and intracellular 
cAMP increased (Figure 41 and the left panel of Figure 43). When receptors are already pre-
clustered at high receptor expression levels, hCG binding has modest effects, if any, on further 
receptor aggregation and in intracellular cAMP level (Figure 42 and the right panel of Figure 43).   
The relationship between receptor expression and receptor aggregation is likely to be 
influenced by the presence on cell membranes of membrane microdomains which appear to 
function as signaling platforms for LHR. LHR accumulate in these microdomains when the 
receptors have clustered. Thus, clusters occur either as a result of high receptor densities or, when 
receptor density is lower, in response to hCG binding to the receptor.  In either case, the clustered 
receptors in microdomains have become more concentrated in comparatively small membrane 
areas and the receptors actively signal.  Disruption of membrane microdomains by MβCD appears 
to disperse at least some of the receptor clusters and reduces intracellular cAMP levels.   
Studies with DG-hCG, an hCG antagonist, suggest that LHR interactions, either in 
response to hCG or as a result of high receptor densities, result from receptor association 
coefficients which can be calculated.  Binding of DG-hCG reduces receptor interactions and, as a 
result, reduces the ability of receptors to signal. This reduction become more significant as the 
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numbers of LHR per cell increased (Figure 44). Experimentally, initial anisotropy values 
increased in DG-hCG treated cells and intracellular cAMP levels decrease.   
These results serve as an important guide to future studies.  First, and most important, they 
provide cautionary guidance to researchers studying GPCR function by demonstrating 
systematically that receptor numbers affect receptor function. With respect to LHR, the receptor 
number per cell or, alternatively, receptor surface density in LH target tissues would provide a 
better understanding of the receptor’s functional state.  As an aside, it is probably important to 
specifically consider receptor density per unit cell surface area in this regard. Total numbers of 
receptor per cell can be similar on cell types such as large and small luteal cells, but these cells 
have  very different sizes [266]. Thus, small cells have receptor densities that are higher while 
larger cells have lower receptor densities. 
To better understand the relationship between expression levels of LHR and physiologic 
function, it would be interesting to have transgenic mouse models where LHR are expressed in 
tissues in higher numbers. These mouse models could provide information on a range of 
behavioral, phenotypic and physiologic effects resulting from receptor overexpression.  One can 
speculate that changes in behavior such as aggression might appear in mice with higher expression 
levels of LHR as a result of an increase of testosterone [39, 267]. In addition, skin changes might 
appear since studies have found LHR in skin [34, 253].  Diseases associated with LHR such as AD 
[56-61] and cancers [33, 62-68] might be modeled in these mice to determine whether LHR are 
involved in disease progression in meaningful ways.  
Pharmacologic agents could also be tested in vivo in mice that overexpress LHR. 
Transgenic mouse models expressing enhanced LHR or knockout of endogenous LHR (LuRKO) 
have been already generated and used successfully in experiments that mimic human disorders 
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related to receptor mutation [39, 51, 147]. Transgenic mouse models expressing low or high 
numbers of LHR per cell are needed for particularly interesting studies. One could, for example, 
monitor mouse behavior related to memory, of interest due to the relationship between LHR 
expression and development of AD, after treatment with pharmacologic agents targeting LHR.  
Compounds that are available or have been used previously would be of interest including 
thienopyridine compounds which are believed to bind to LHR receptors and increase downstream 
steroidogenesis [268] and deslorelin acetate which increases expression of LHR [269].  Drugs 
already in clinical use include triptorelin, leuprolide, goserelin and buserelin which increase LHR 
expression and are used in the treatment of infertility, uterine fibroids, endometriosis and sex-
hormone sensitive cancers associated with low expression levels of LHR [270-272].  LH 
antagonists such as T-98475, cetrorelix, ganirelix, degarelix, and abarelix  [33, 65, 271, 273-277] 
may be involved in remission of tumors that overexpress LHR.  Furthermore, vanadium 
compounds have been found to increase the aggregation of LHR and induce its activity [278]. 
The receptor aggregation state would also be of interest in response to treatment of cell 
lines with micro RNAs.  An 18-nucleotide segment of non-coding RNA, miR-112, regulates the 
expression of LHR by controlling the expression of LHR mRNA-binding protein.  This molecule 
plays a role in controlling the degradation rate of mRNA for LHR [279] and might be of interest.  
Other studies found miR-136-3p and miR-513a-3p decrease the expression of LHR [280, 281].  
Gene therapy with micro-RNAs might be useful in regulating the expression of LHR in pathologic 
conditions. 
Finally, it might be interesting to explore ways of targeting non-gonadal tissues so that 
LHR could be expressed at appropriate levels.   Previous studies have found that LHR are 
expressed in the retina and have a role in reducing visual processing. They may also affect 
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development of eyes in the fetus [253, 254].  Although there is no pathology associated with LHR 
expression in the eye, it seems likely that this may exist.  LHR expressed in skin might possibly 
explain skin changes in menopausal women [34].  Studies using transgenic knockout LHR mice 
provide evidence that the absence of LHR significantly reduces amyloid beta load in brains. 
amyloid beta load is a problem for patients with AD [56-60].  A better understanding of the 
relationship between LHR expression levels and memory, vision, skin properties, etc. in transgenic 
mice and monitoring changes following treatments with available drugs may more fully elucidate 















Figure 42: Relationship between the size of LHR clusters and production of cAMP in cells 









    
 
 
Figure 43: Relationship between the size of LHR clusters and production of cAMP in cells 





Figure 44: LHR expression levels affect the cluster size and activity of LHR in response to hCG. 
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Figure A1: Calibration curve for conversion the receptors number per cell in flow cytometry to 
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Figure A2: The correlation between anisotropy and receptors number per μm2 during 
photobleaching in untreated cells. Symbols indicate average data for cells representing the four 
expression groups. This figure indicates that the oligomerization state of LHR is highly dependent 
on the receptors number of LHR per cell. Data are presented in each point as the mean ± SEM for 
n=10 measurements; The four cell lines were significantly different in one-way ANOVA and 




































Figure A3: The correlation between anisotropy and receptors number per μm2 during 
photobleaching in cells treated with hCG. Symbols indicate average data for cells representing the 
four expression groups. This figure indicates that the oligomerization state of LHR is highly 
dependent on the receptors number of LHR per cell. Data are presented in each point as the mean 
± SEM for n=10 measurements; The four cell lines were significantly different in one-way 



































GPCR  G protein-coupled receptors  
LHR Luteinizing hormone receptors 
LH Luteinizing hormone 
hCG Human chorionic gonadotropin 
DG-hCG Deglycosylated human chorionic gonadotropin 
T2R Taste receptors  
7TM Seven hydrophobic transmembrane 
GTP  Guanosine triphosphate 
GDP Guanosine diphosphate 
AC Adenylyl cyclase 
α Alpha  
γ  Gamma 
β Beta 
ATP Adenosine triphosphate 
cAMP Cyclic adenosine monophosphate 
PDE Phosphodiesterase  
cGMP Cyclic guanosine monophosphate 
GMP Guanosine monophosphate 
PLC Phospholipase C 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
DAG Diacylglycerol 
PKC Protein kinase C 
IP3 Inositol triphosphate 
Ca+2 Calcium ion 
K+ Potassium  
CL Corpus luteum 
FSH Follicle stimulating hormone 
GnRH Gonadotropin releasing hormone 
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RPKM Reads Per Kilobase Million 
LCH Leydig cell hypoplasia 
FMPP Familial male-limited precocious puberty 
AD Alzheimer disease 
Aβ Β-amyloid peptide 
GPHRs  Glycoprotein hormone receptors 
ECD Extracellular domain 
LRRs Leucine rich repeats 
ECLs Three extracellular loops 
ICLs Intracellular loops 
ICD Intracellular domain 
hLH Humane luteinizing hormone 
Da Dalton 
PKB Protein kinase B 
ERK Extracellular signal-regulated kinases 
HF Hydrogen fluoride 
TFMS Trifluoromethanesulfonic acid  
LHRcAMP− Luteinizing hormone receptor unable to signal  
LHRLH− Luteinizing hormone receptor unable to bind hormone 
PKA Protein kinase A 
EPAC Exchange protein directly activated by camp 
CREB Camp-response element-binding protein 
P38 MAPK P38 mitogen-activated protein kinases 
STAR Steroidogenic acute regulatory  
P450scc P450 cholesterol side chain cleavage enzyme 
mTORC1 Rapamycin complex 1 
PKB Protein kinase B   
EGFRs Epidermal growth factor receptors 
IGF-I Insulin-like growth factor 1 receptors 
ERK1/2 Extracellular signal-regulated kinases 1 and 2 
SFKs Src family of kinases 
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ARNO Arf nucleotide binding site opener 
ARF6 ADP ribosylation factor 6  
MβCD Methyl-β-cyclodextrin 
GPI Glycosyl phosphatidyl inositol 
FCCS Fluorescence cross-correlation spectroscopy 
homo-FRET Homo-transfer fluorescence resonance energy transfer 
hetero-FRET  Hetero-transfer fluorescence resonance energy transfer 
BRET  Bioluminescence resonance energy transfer 
PD-PALM Dual-color photoactivatable dyes and localization microscopy  
FPR Fluorescence photobleaching recovery  
BiFC Bimolecular fluorescence complementation 
Å Angstroms 
R0 Förster distance 
E Efficiency of FRET 
HSV-1 Herpes simplex virus 




G G factor 
RG6 Rhodamine 6G 
eYFP  Enhanced yellow fluorescent protein 
9   Rotation correlation 
:D Fluorescence lifetime 
RIA Radioimmunoassay  
ECLIA Electrochemiluminescence immunoassays  
ELISA Enzyme-linked immunosorbent assays  
HTRF Homogeneous time-resolved fluorescence  
CAMYEL  Camp sensor using YFP-Epac-rluc 
ICUE  Indicator of camp Using Epac 
eCFP Enhanced cyan fluorescence protein  
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cpV-L194 Circularly permuted Venus at lysine 194 of eyfp  
IVF In vitro fertilization 
IVM In vitro maturation 
CHO Chinese hamster ovary 
DMEM Dulbecco’s Modified Eagle medium  
G418 Genticin 
FBS Fetal bovine serum 
P/S Penicillin/streptomycin  
EDTA  Ethylenediaminetetraacetic acid 
GFP Green fluorescence protein 
PVDF Polyvinylidene fluoride or polyvinylidene difluoride 
TBST Tris Buffered Saline with Tween 
PBS Phosphate-buffered saline 
MDL-12,330a 
hydrochloride 
Cis-N-(2-Phenylcyclopentyl)-azacyclotridec-1-en-2-amine   
Hydrochloride 
FITC  Fluorescein isothiocyanate 
MESF Molecules of equivalent soluble fluorophores 
r0 Fundamental anisotropy 
YFPSE YFP sensitized emission 
SEM Standard error of the mean 
LuRK0 Transgenic mouse knockout of endogenous LHR 
  
  
  
  
  
  
 
 
 
